tranexamic acid has been researched along with Postpartum Hemorrhage in 210 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Postpartum Hemorrhage: Excess blood loss from uterine bleeding associated with OBSTETRIC LABOR or CHILDBIRTH. It is defined as blood loss greater than 500 ml or of the amount that adversely affects the maternal physiology, such as BLOOD PRESSURE and HEMATOCRIT. Postpartum hemorrhage is divided into two categories, immediate (within first 24 hours after birth) or delayed (after 24 hours postpartum).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although prophylactic tranexamic acid administration after cesarean delivery resulted in a lower incidence of calculated estimated blood loss of >1000 mL or red cell transfusion by day 2, its failure to reduce the incidence of hemorrhage-related secondary clinical outcomes (TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery trial) makes its use questionable." | 9.51 | Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery randomized clinical trial. ( Azria, E; Benard, A; Bohec, C; Bouchghoul, H; Bretelle, F; Chauleur, C; Daniel, V; Darsonval, A; de Marcillac, F; Deneux-Tharaux, C; Desbrière, R; Froeliger, A; Fuchs, F; Gallot, D; Gauchotte, E; Georget, A; Haddad, B; Kayem, G; Korb, D; Le Lous, M; Le Ray, C; Legendre, G; Letouzey, V; Madar, H; Mattuizzi, A; Mottet, N; Parant, O; Perrotin, F; Regueme, S; Roussillon, C; Rozenberg, P; Salomon, LJ; Sananès, N; Sénat, MV; Sentilhes, L; Vardon, D; Verspyck, E; Winer, N, 2022) |
| "The evidence that early tranexamic acid treatment reduces postpartum hemorrhage deaths has major implications for obstetrical care worldwide." | 9.41 | Tranexamic acid for bleeding: Much more than a treatment for postpartum hemorrhage. ( Brenner, A; Roberts, I; Shakur-Still, H, 2023) |
| "To conduct the first-ever systematic review and meta-analysis of randomized controlled trials (RCTs) on the antihemorrhagic utility and safety of tranexamic acid (TXA) versus misoprostol for management (prevention and/or treatment) of postpartum hemorrhage (PPH)." | 9.41 | Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. ( Abdulmalik, NA; Abu-Zaid, A; Abuzaid, M; Albadawi, MI; Alblewi, H; Albouq, B; Alomar, O; Alsehaimi, SO; Alyousef, A; Baradwan, S; Bukhari, IA; Ghazi, A; Khadawardi, K; Salem, H, 2023) |
| "An antifibrinolytic agent that blocks lysine-binding sites on plasminogen molecules, tranexamic acid reduces bleeding-related mortality in women with postpartum hemorrhage (PPH), especially administered fairly soon after delivery." | 9.34 | TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. ( Daniel, V; Deneux-Tharaux, C; Sentilhes, L, 2020) |
| " This trial assessed the efficacy, safety, and acceptability of oral TXA when used as an adjunct to sublingual misoprostol to treat postpartum hemorrhage (PPH) following vaginal delivery." | 9.34 | A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. ( Abbas, D; Diop, A; Martin, R; Ngoc, NTN; Razafi, A; Tuyet, HTD; Winikoff, B, 2020) |
| "To investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone bilateral uterine arteryligation (BUAL)." | 9.30 | Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial. ( Abbas, AM; Sallam, HF; Shady, NW, 2019) |
| "This study was designed to compare the effect of intravenous tranexamic acid (TXA) and prostaglandin analogue on reducing PPH resulted from uterine atony in women undergoing C section or vaginal delivery." | 9.27 | The Effect of Tranexamic Acid on Preventing Post-partum Hemorrhage Due to Uterine Atony: A Triple-blind Randomized Clinical Trial. ( Ahmadi, M; Nikbakht, R; Zargar, M, 2018) |
| "Tranexamic acid (TXA) effectively reduces bleeding in women with postpartum hemorrhage (PPH) in hospital settings." | 9.22 | Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review. ( Bar-Zeev, S; Schulte-Hillen, C; Tran, NT; Zeck, W, 2022) |
| "To assess whether a policy of routine administration of high-dose tranexamic acid (TA) at the diagnosis of postpartum hemorrhage (PPH) reduces blood loss after vaginal birth." | 9.22 | Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. ( Bouet, PE; Descamps, P; Gillard, P; Legendre, G; Ruiz, V; Sentilhes, L, 2016) |
| "To assess the effects of tranexamic acid among patients undergoing cesarean delivery who were at high risk of postpartum hemorrhage." | 9.22 | Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. ( Aneja, A; Hanjoora, VM; Kaur, R; Khanna, M; Sujata, N; Tobin, R, 2016) |
| "Nine databases were searched using variations of keywords 'tranexamic acid', 'postpartum hemorrhage' and 'cost effectiveness'." | 9.12 | The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review. ( Aziz, S; Comrie-Thomson, L; Homer, CSE; Rossiter, S; Scott, N; Vogel, JP; Wilson, AN, 2021) |
| "Tranexamic acid (TA) has been demonstrated to reduce blood loss and the incidences of postpartum hemorrhage (PPH) during caesarean sections." | 9.05 | Tranexamic acid for postpartum hemorrhage prevention in vaginal delivery: A meta-analysis. ( Griffiths, BB; Xia, Y; Xue, Q, 2020) |
| "There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding." | 8.91 | The current place of tranexamic acid in the management of bleeding. ( Hunt, BJ, 2015) |
| "The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage." | 8.87 | Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011) |
| "This study was a pre- and postimplementation analysis of concomitant uterine artery embolization and tranexamic acid in cases of patients with antenatally suspected placenta increta and percreta over a 5-year period (2018-2022)." | 8.31 | Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. ( Blankenship, LM; McCann, GA; Munoz, JL; Ramsey, PS, 2023) |
| "The administration of tranexamic acid to a theoretical cohort of 100,000 women would prevent 11 maternal deaths, 6 postpartum laparotomies after vaginal delivery, and 112 reoperations after cesarean delivery." | 8.12 | Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. ( Caughey, AB; D'Souza, R; Howard, DC; Jones, AE; Lai, J; Skeith, A, 2022) |
| "To check the quality of oxytocin and tranexamic acid-two recommended products for prevention and treatment of postpartum hemorrhage (PPH)-used in facilities taking part in an implementation research project to improve PPH diagnosis and management." | 8.12 | Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania. ( Alwy Al-Beity, FM; Ammerdorffer, A; Beeson, L; Coomarasamy, A; Devall, AJ; Galadanci, H; Gallos, ID; Gülmezoglu, AM; Hofmeyr, GJ; Lambert, P; Mammoliti, KM; Qureshi, Z; Rushwan, S; Singata-Madliki, M; Timms, R; Wright, P, 2022) |
| "The objective of this review is to evaluate the effectiveness of intravenous administration of tranexamic acid (TXA) within three hours of birth in mothers with a diagnosis of postpartum hemorrhage (PPH)." | 7.91 | Tranexamic acid as adjuvant treatment for postpartum hemorrhage: a systematic review protocol. ( Bonanno, LS; Fahrenholtz, CG; Martin, JB, 2019) |
| "When used in conjunction with the standard of care, 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery is associated with a significant reduction in maternal mortality from postpartum hemorrhage (PPH) (strength of recommendation: A, randomized controlled trial [RCT] and Cochrane review)." | 7.91 | Does tranexamic acid reduce mortality in women with postpartum hemorrhage? ( Dresang, L; Kredit, S; Vellardita, L, 2019) |
| "The World Maternal Antifibrinolytic trial demonstrated that tranexamic acid administered during postpartum hemorrhage reduces hemorrhage-related mortality and laparotomies." | 7.91 | Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. ( Einerson, BD; Shainker, SA; Sudhof, LS, 2019) |
| "Recent results show a protective effect of tranexamic acid on death due to bleeding in patients with postpartum hemorrhage in low- and middle-resource countries." | 7.85 | The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. ( Bloemenkamp, KWM; Caram-Deelder, C; Eikenboom, J; Gillissen, A; Henriquez, DDCA; van den Akker, T; van der Bom, JG; van Roosmalen, J; Wind, M; Zwart, JJ, 2017) |
| "Tranexamic acid has been found to be both effective and safe for decreasing maternal mortality in women with postpartum hemorrhage, and prophylactic use of tranexamic acid may decrease the need for packed red blood cell transfusions and/or uterotonics." | 7.01 | Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. ( Eke, AC; Federspiel, JJ; Jones, AJ, 2023) |
| "Tranexamic acid (TXA) has been investigated as a potential adjunct therapy to uterotonics within this setting." | 6.58 | Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes. ( Ahmadzia, HK; James, AH; Katler, QS; Phillips, JM, 2018) |
| "Placenta previa affects approximately 4 per 1000 pregnancies and increases the risk of antepartum bleeding, emergent preterm labour and emergency caesarean sections." | 5.91 | Use of tranexamic acid (TXA) to reduce preterm birth and other adverse obstetrical outcomes among pregnant individuals with placenta previa: a systematic review protocol. ( Muldoon, KA; Seguin, N; Visintini, S; Walker, M, 2023) |
| "Tranexamic acid (TXA) has been shown to reduce PPH complications although it is not routinely recommended for use as prophylaxis to date." | 5.91 | Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis. ( Ahmadzia, HK; Dazelle, WDH; Ebner, MK; Kazma, J; Potarazu, SN, 2023) |
| "Prophylactic use of tranexamic acid during cesarean delivery did not lead to a significantly lower risk of a composite outcome of maternal death or blood transfusion than placebo." | 5.69 | Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery. ( Bailit, JL; Chauhan, SP; Clifton, RG; Dalton, W; Grobman, WA; Gyamfi-Bannerman, C; Longo, M; Macones, GA; Metz, TD; Pacheco, LD; Parry, S; Rood, K; Rouse, DJ; Saade, GR; Salazar, A; Simhan, HN; Thorp, JM; Tita, ATN; Weiner, SJ, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic pharmacologic agent with demonstrated effectiveness for reducing the incidence of death from blood loss following trauma and major surgery." | 5.56 | The Use of Tranexamic Acid to Prevent Postpartum Hemorrhage. ( Mielke, RT; Obermeyer, S, 2020) |
| "The American College of Obstetricians and Gynecologists states that the current data are insufficient to recommend tranexamic acid prophylaxis for postpartum hemorrhage." | 5.51 | Tranexamic acid for prevention of hemorrhage in elective repeat cesarean delivery-a randomized study. ( Duryea, EL; Eddins, MM; Klucsarits, SE; Leveno, KJ; McIntire, DD; Nelson, DB; Ogunkua, OT, 2022) |
| "Although prophylactic tranexamic acid administration after cesarean delivery resulted in a lower incidence of calculated estimated blood loss of >1000 mL or red cell transfusion by day 2, its failure to reduce the incidence of hemorrhage-related secondary clinical outcomes (TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery trial) makes its use questionable." | 5.51 | Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery randomized clinical trial. ( Azria, E; Benard, A; Bohec, C; Bouchghoul, H; Bretelle, F; Chauleur, C; Daniel, V; Darsonval, A; de Marcillac, F; Deneux-Tharaux, C; Desbrière, R; Froeliger, A; Fuchs, F; Gallot, D; Gauchotte, E; Georget, A; Haddad, B; Kayem, G; Korb, D; Le Lous, M; Le Ray, C; Legendre, G; Letouzey, V; Madar, H; Mattuizzi, A; Mottet, N; Parant, O; Perrotin, F; Regueme, S; Roussillon, C; Rozenberg, P; Salomon, LJ; Sananès, N; Sénat, MV; Sentilhes, L; Vardon, D; Verspyck, E; Winer, N, 2022) |
| "The evidence that early tranexamic acid treatment reduces postpartum hemorrhage deaths has major implications for obstetrical care worldwide." | 5.41 | Tranexamic acid for bleeding: Much more than a treatment for postpartum hemorrhage. ( Brenner, A; Roberts, I; Shakur-Still, H, 2023) |
| "Tranexamic acid is a cost-effective intervention for the prevention of postpartum hemorrhage among women who undergo cesarean delivery, but the evidence to support its use is conflicting." | 5.41 | Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials. ( Ahmad, AB; Ayyan, M; Azeem, S; Cheema, HA; Ehsan, M; Hussain, A; Laganà, AS; Mikuš, M; Nashwan, AJ; Shahid, A, 2023) |
| "To conduct the first-ever systematic review and meta-analysis of randomized controlled trials (RCTs) on the antihemorrhagic utility and safety of tranexamic acid (TXA) versus misoprostol for management (prevention and/or treatment) of postpartum hemorrhage (PPH)." | 5.41 | Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. ( Abdulmalik, NA; Abu-Zaid, A; Abuzaid, M; Albadawi, MI; Alblewi, H; Albouq, B; Alomar, O; Alsehaimi, SO; Alyousef, A; Baradwan, S; Bukhari, IA; Ghazi, A; Khadawardi, K; Salem, H, 2023) |
| "An antifibrinolytic agent that blocks lysine-binding sites on plasminogen molecules, tranexamic acid reduces bleeding-related mortality in women with postpartum hemorrhage (PPH), especially administered fairly soon after delivery." | 5.34 | TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. ( Daniel, V; Deneux-Tharaux, C; Sentilhes, L, 2020) |
| " This trial assessed the efficacy, safety, and acceptability of oral TXA when used as an adjunct to sublingual misoprostol to treat postpartum hemorrhage (PPH) following vaginal delivery." | 5.34 | A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. ( Abbas, D; Diop, A; Martin, R; Ngoc, NTN; Razafi, A; Tuyet, HTD; Winikoff, B, 2020) |
| "To investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone bilateral uterine arteryligation (BUAL)." | 5.30 | Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial. ( Abbas, AM; Sallam, HF; Shady, NW, 2019) |
| "This study was designed to compare the effect of intravenous tranexamic acid (TXA) and prostaglandin analogue on reducing PPH resulted from uterine atony in women undergoing C section or vaginal delivery." | 5.27 | The Effect of Tranexamic Acid on Preventing Post-partum Hemorrhage Due to Uterine Atony: A Triple-blind Randomized Clinical Trial. ( Ahmadi, M; Nikbakht, R; Zargar, M, 2018) |
| "The use of tranexamic acid reduces mortality due to postpartum hemorrhage." | 5.27 | Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. ( Azria, E; Bohec, C; Chrétien, JM; Daniel, V; Darsonval, A; Deneux-Tharaux, C; Deruelle, P; Desbrière, R; Doret-Dion, M; Ducarme, G; Fuchs, F; Huissoud, C; Kayem, G; Le Ray, C; Perrotin, F; Seco, A; Sénat, MV; Sentilhes, L; Vardon, D; Winer, N, 2018) |
| "During the third stage of labor, oxytocin and tranexamic acid, oxytocin and misoprostol, oxytocin and methylergometrine, or carbetocin is recommended for the prevention of postpartum hemorrhage after vaginal delivery." | 5.22 | Evidence-based labor management: third stage of labor (part 5). ( Angarita, AM; Berghella, V, 2022) |
| "Tranexamic acid (TXA) effectively reduces bleeding in women with postpartum hemorrhage (PPH) in hospital settings." | 5.22 | Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review. ( Bar-Zeev, S; Schulte-Hillen, C; Tran, NT; Zeck, W, 2022) |
| "To assess whether a policy of routine administration of high-dose tranexamic acid (TA) at the diagnosis of postpartum hemorrhage (PPH) reduces blood loss after vaginal birth." | 5.22 | Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. ( Bouet, PE; Descamps, P; Gillard, P; Legendre, G; Ruiz, V; Sentilhes, L, 2016) |
| "To assess the effects of tranexamic acid among patients undergoing cesarean delivery who were at high risk of postpartum hemorrhage." | 5.22 | Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. ( Aneja, A; Hanjoora, VM; Kaur, R; Khanna, M; Sujata, N; Tobin, R, 2016) |
| "In this double-blind randomised controlled trial, 120 women with a singleton pregnancy were randomly allocated to receive either one gram intravenous TA or placebo in addition to 10 IU oxytocin after delivery of the fetus." | 5.20 | The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum haemorrhage: a double-blind randomised controlled trial. ( Abbasalizadeh, F; Mirghafourvand, M; Mohammad-Alizadeh, S; Shirdel, M, 2015) |
| "Nine databases were searched using variations of keywords 'tranexamic acid', 'postpartum hemorrhage' and 'cost effectiveness'." | 5.12 | The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review. ( Aziz, S; Comrie-Thomson, L; Homer, CSE; Rossiter, S; Scott, N; Vogel, JP; Wilson, AN, 2021) |
| " Systematic review and meta-analysis to determine the bleeding rates associated with tranexamic acid, desmopressin, platelet transfusion, plasma transfusion and recombinant activated factor VII, for patients with unclassified bleeding disorders undergoing surgery, childbirth or with menorrhagia." | 5.12 | Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies. ( Desborough, MJR; Doree, C; Lowe, GC; Obaji, S; Thomas, W, 2021) |
| " Tranexamic acid (TXA) is one of the most commonly used and widely researched antifibrinolytic agents; its role in postpartum hemorrhage, menorrhagia, trauma-associated hemorrhage, and surgical bleeding has been well defined." | 5.05 | The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. ( Al-Samkari, H; Cai, J; DeLoughery, TG; Olson, S; Raghunathan, V; Ribkoff, J; Shatzel, JJ, 2020) |
| "Tranexamic acid (TA) has been demonstrated to reduce blood loss and the incidences of postpartum hemorrhage (PPH) during caesarean sections." | 5.05 | Tranexamic acid for postpartum hemorrhage prevention in vaginal delivery: A meta-analysis. ( Griffiths, BB; Xia, Y; Xue, Q, 2020) |
| " The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders." | 4.98 | Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018) |
| "There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding." | 4.91 | The current place of tranexamic acid in the management of bleeding. ( Hunt, BJ, 2015) |
| "This review summarizes the background, current evidence and recommendations with regard to the role of fibrinogen, tranexamic acid, prothrombin complex concentrate, desmopressin, and recombinant factor VIIa in the treatment of patients with postpartum hemorrhage." | 4.91 | Hemostatic resuscitation in postpartum hemorrhage - a supplement to surgery. ( Afshari, A; Albrechtsen, CK; Ekelund, K; Hanke, G; Stensballe, J; Wikkelsøe, A, 2015) |
| "The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage." | 4.87 | Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011) |
| "The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives." | 4.31 | Tranexamic acid at cesarean delivery: drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2023) |
| "The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives." | 4.31 | Tranexamic acid at cesarean delivery: Drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2023) |
| "The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives." | 4.31 | Tranexamic acid at cesarean delivery: drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2023) |
| "This prospective cohort study was based on data from the Tranexamic Acid for Preventing Postpartum Hemorrhage after Cesarean Delivery (TRAAP2) trial, a multicenter, randomized, placebo-controlled trial that took place from March 2018 through January 2020 (23 months)." | 4.31 | Association Between Surgeon Gender and Maternal Morbidity After Cesarean Delivery. ( Bénard, A; Bouchghoul, H; Deneux-Tharaux, C; Georget, A; Madar, H; Sentilhes, L, 2023) |
| "Nationally, a higher percentage of patients received tranexamic acid without a postpartum hemorrhage diagnosis compared with previous studies, and the western region of the United States had an overall increased use of tranexamic acid during delivery compared with previous years." | 4.31 | An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021. ( Ahmadzia, HK; Dazelle, WDH; Litman, EA; Sterling, EK, 2023) |
| "This study was a pre- and postimplementation analysis of concomitant uterine artery embolization and tranexamic acid in cases of patients with antenatally suspected placenta increta and percreta over a 5-year period (2018-2022)." | 4.31 | Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. ( Blankenship, LM; McCann, GA; Munoz, JL; Ramsey, PS, 2023) |
| "Treatment with tranexamic acid (TxA) significantly reduces maternal death due to postpartum hemorrhage." | 4.12 | The effect of prophylactic use of tranexamic acid for cesarean section. ( Binyamin, Y; Erez, O; Frank, D; Frenkel, A; Gruzman, I; Heesen, M; Ioscovich, A; Lerman, S; Orbach-Zinger, S; Zlotnik, A, 2022) |
| "The administration of tranexamic acid to a theoretical cohort of 100,000 women would prevent 11 maternal deaths, 6 postpartum laparotomies after vaginal delivery, and 112 reoperations after cesarean delivery." | 4.12 | Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. ( Caughey, AB; D'Souza, R; Howard, DC; Jones, AE; Lai, J; Skeith, A, 2022) |
| "To check the quality of oxytocin and tranexamic acid-two recommended products for prevention and treatment of postpartum hemorrhage (PPH)-used in facilities taking part in an implementation research project to improve PPH diagnosis and management." | 4.12 | Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania. ( Alwy Al-Beity, FM; Ammerdorffer, A; Beeson, L; Coomarasamy, A; Devall, AJ; Galadanci, H; Gallos, ID; Gülmezoglu, AM; Hofmeyr, GJ; Lambert, P; Mammoliti, KM; Qureshi, Z; Rushwan, S; Singata-Madliki, M; Timms, R; Wright, P, 2022) |
| "The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives." | 4.12 | Tranexamic acid at cesarean delivery: drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2022) |
| "This study aimed to determine the optimal tranexamic acid dose needed to prevent postpartum hemorrhage." | 4.02 | Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. ( Ahmadzia, HK; Berger, JS; Gobburu, JVS; Guo, D; James, AH; Li, S; Luban, NLC; Miszta, A; van den Anker, J; Wolberg, AS, 2021) |
| "Within 2245 included ICSRs on tranexamic acid, we identified 29 reports of adverse renal vascular and ischemic conditions, 42 reports of pulmonary thrombotic and embolic conditions, and 41 reports of peripheral embolism and thrombosis." | 4.02 | Renal ischemic adverse drug events related to tranexamic acid in women of child-bearing age: an analysis of pharmacovigilance data. ( Burden, AM; Heesen, M; Stämpfli, D; Weiler, S; Weiniger, CF, 2021) |
| "The objective of this review is to evaluate the effectiveness of intravenous administration of tranexamic acid (TXA) within three hours of birth in mothers with a diagnosis of postpartum hemorrhage (PPH)." | 3.91 | Tranexamic acid as adjuvant treatment for postpartum hemorrhage: a systematic review protocol. ( Bonanno, LS; Fahrenholtz, CG; Martin, JB, 2019) |
| "When used in conjunction with the standard of care, 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery is associated with a significant reduction in maternal mortality from postpartum hemorrhage (PPH) (strength of recommendation: A, randomized controlled trial [RCT] and Cochrane review)." | 3.91 | Does tranexamic acid reduce mortality in women with postpartum hemorrhage? ( Dresang, L; Kredit, S; Vellardita, L, 2019) |
| "We recognized a correlation between the publication of the WOMAN trial and the administration of tranexamic acid at an early time-point in all standard operating procedures of the participating institutions to treat postpartum hemorrhage." | 3.91 | Influence of the WOMAN trial on national wide standard operating procedures for treatment of postpartum hemorrhage. ( Jennewein, L; Louwen, F; Möllmann, CJ; Raddatz, LM; Raimann, FJ; Sonntagbauer, M; Weber, CF; Zacharowski, K, 2019) |
| "The World Maternal Antifibrinolytic trial demonstrated that tranexamic acid administered during postpartum hemorrhage reduces hemorrhage-related mortality and laparotomies." | 3.91 | Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. ( Einerson, BD; Shainker, SA; Sudhof, LS, 2019) |
| "Recent results show a protective effect of tranexamic acid on death due to bleeding in patients with postpartum hemorrhage in low- and middle-resource countries." | 3.85 | The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. ( Bloemenkamp, KWM; Caram-Deelder, C; Eikenboom, J; Gillissen, A; Henriquez, DDCA; van den Akker, T; van der Bom, JG; van Roosmalen, J; Wind, M; Zwart, JJ, 2017) |
| " We sought to determine the impact of tranexamic acid and ɛ-aminocaproic acid on in vitro clotting properties in pregnancy." | 3.85 | Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? ( Ahmadzia, HK; Grotegut, CA; Hoffman, MR; James, AH; Lockhart, EL; Murtha, AP; Swamy, GK; Thomas, SM; Welsby, IJ, 2017) |
| " A rapid recourse to prostaglandins (sulprostone in France) may reverse uterine atony." | 3.83 | Major obstetric hemorrhage. ( Le Gouez, A; Mercier, FJ, 2016) |
| "Delays in the detection or treatment of postpartum hemorrhage can result in complications or death." | 3.30 | Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage. ( Akter, S; Althabe, F; Alwy Al-Beity, F; Ammerdorffer, A; Arends, E; Aswat, A; Beeson, L; Bohren, MA; Coomarasamy, A; Devall, A; Evans, C; Fawcus, S; Forbes, G; Galadanci, H; Gallos, I; Gülmezoglu, M; Gwako, G; Hemming, K; Hofmeyr, GJ; Horne, I; Latthe, P; Lissauer, D; Lorencatto, F; Mammoliti, KM; Martin, J; Meher, S; Middleton, L; Miller, S; Moran, N; Muhammad, S; Mwampashi, A; Nausheen, S; Okore, J; Oladapo, OT; Osoti, A; Podesek, M; Qureshi, Z; Roberts, T; Sheikh, L; Shennan, A; Sindhu, KN; Singata-Madliki, M; Smith, JM; Timms, R; Wakili, AA; Weeks, A; Widmer, M; Williams, E; Yunas, I, 2023) |
| "Tranexamic acid (TXA) is a life-saving treatment for women with PPH." | 3.30 | Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I'M WOMAN). ( Arribas, M; Bello, A; Brenner, A; Chaudhri, R; Javid, K; Kayani, A; Muganyizi, P; Olayemi, O; Roberts, I; Shakur-Still, H, 2023) |
| "Tranexamic acid concentration was measured with liquid chromatography-mass spectrometry, and the parameters of the pharmacokinetic models were estimated using population pharmacokinetics." | 3.11 | Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. ( Arribas, M; Bouazza, N; Foissac, F; Grassin-Delyle, S; Lamy, E; Roberts, I; Runge, I; Semeraro, M; Shakur-Still, H; Treluyer, JM; Urien, S, 2022) |
| "Tranexamic acid (TXA) is a useful drug for prevention of PPH and merits evaluation in Nigeria, where PPH is the leading cause of maternal death (25%) and severe maternal morbidity." | 3.11 | Tranexamic acid for reducing blood loss following vaginal delivery: a double-blind randomized controlled trial. ( Dimejesi, BI; Igboke, FN; Lawani, LO; Obi, VO, 2022) |
| " Pharmacokinetic-pharmacodynamic modelling of these data might identify the best pharmacodynamic monitoring criteria and the optimal tranexamic acid dosing regimen for treatment of postpartum haemorrhage." | 3.11 | Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. ( Allorge, D; Broisin, F; Constant, B; Ducloy-Bouthors, AS; Duhamel, A; Faraoni, D; Favier, R; Ghesquiere, L; Gilliot, S; Gouez, AL; Hennart, B; Jeanpierre, E; Keita-Meyer, H; Kyheng, M; Lebuffe, G; Moyanotidou, G; Odou, P; Peynaud, E; Rigouzzo, A; Susen, S; Turbelin, A, 2022) |
| "The purpose of the present study was to find the effects of TXA on the amount of bleeding following vaginal delivery and its adverse effects." | 3.11 | Effects of tranexamic acid on the amount of bleeding following vaginal delivery and its adverse effects: a double-blind placebo controlled randomized clinical trial. ( Dadkhah, F; Kashanian, M; Sheikhansari, N; Tabatabaei, N, 2022) |
| "Tranexamic acid has been found to be both effective and safe for decreasing maternal mortality in women with postpartum hemorrhage, and prophylactic use of tranexamic acid may decrease the need for packed red blood cell transfusions and/or uterotonics." | 3.01 | Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. ( Eke, AC; Federspiel, JJ; Jones, AJ, 2023) |
| "Tranexamic acid has been found to be a good choice for reducing blood loss during and after delivery in Africa regardless of the mode of delivery." | 3.01 | Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis. ( Abdurke, M; Ahmed, F; Alemu, A; Amare, G; Amin, A; Balcha, T; Balis, B; Bekele, H; Debella, A; Degefa, M; Eshetu, B; Eyeberu, A; Getachew, A; Getachew, T; Habte, S; Lemi, M; Mohammed, A; Musa, I; Negash, A; Tefera, T; Yadeta, E, 2023) |
| "Tranexamic acid (TXA) has been shown to reduce blood loss and blood product transfusion requirements." | 3.01 | Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator-induced hyperfibrinolysis in full-term pregnant women: a prospective interventional study. ( Faraoni, D; Lechien, A; Van der Linden, P, 2021) |
| "The primary outcome was postpartum hemorrhage, defined as a calculated estimated blood loss greater than 1000 ml or receipt of a red-cell transfusion within 2 days after delivery." | 3.01 | Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. ( Azria, E; Benard, A; Bohec, C; Bretelle, F; Chauleur, C; Daniel, V; Darsonval, A; de Marcillac, F; Deneux-Tharaux, C; Desbrière, R; Fuchs, F; Gallot, D; Gauchotte, E; Georget, A; Haddad, B; Kayem, G; Korb, D; Le Lous, M; Le Ray, C; Legendre, G; Letouzey, V; Madar, H; Mattuizzi, A; Mottet, N; Parant, O; Perrotin, F; Regueme, S; Roussillon, C; Rozenberg, P; Salomon, LJ; Sananès, N; Sénat, MV; Sentilhes, L; Vardon, D; Verspyck, E; Winer, N, 2021) |
| "Hemorrhage is a leading cause of death after trauma and childbirth." | 2.94 | Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials. ( Bates, I; Bello, A; Chaudhri, R; Kolin, DA; Roberts, I; Shakur-Still, H, 2020) |
| " TA efficiency and optimal dosage in haemorrhagic caesarean section (CS) has not been yet determined." | 2.87 | Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial. ( Allorge, D; Baptiste, AS; Bouthors, AS; Duhamel, A; Hennart, B; Jeanpierre, E; Lannoy, D; Saidi, I; Simon, E; Susen, S, 2018) |
| "Tranexamic acid (TXA) has been shown to be a safe, effective and inexpensive therapeutic option for the treatment of PPH, however, its use prophylactically in mitigating the risk of PPH is unknown." | 2.84 | Protocol for a pilot, randomised, double-blinded, placebo-controlled trial of prophylactic use of tranexamic acid for preventing postpartum haemorrhage (TAPPH-1). ( Alam, A; Au, S; Barrett, J; Bopardikar, A; Callum, J; Choi, S; Kiss, A, 2017) |
| "Tranexamic acid (TA) has been proposed for preventing or treating primary postpartum haemorrhage (PPH), which is the leading cause of maternal morbidity and mortality worldwide." | 2.82 | Tranexamic acid for the prevention and the treatment of primary postpartum haemorrhage: a systematic review. ( Casarin, J; Cromi, A; Ferrari, FA; Franchi, M; Garzon, S; Ghezzi, F; Raffaelli, R; Uccella, S, 2022) |
| "Uterine atony is the most common cause of PPH and local guidelines for uterotonic drug selection should be followed." | 2.82 | Protocol for postpartum haemorrhage including massive transfusion. ( Karlsson, O, 2022) |
| " Future pharmacodynamic analyses will focus on the appropriateness of TXA dosing regimens with regard to the intensity of fibrinolysis in catastrophic obstetric events." | 2.82 | The role of tranexamic acid in the management of postpartum haemorrhage. ( Bouthors, AS; Deneux-Tharaux, C; Gilliot, S; Hennart, B; Jeanpierre, E; Lebuffe, G; Odou, P; Sentilhes, L, 2022) |
| "The frequency of postpartum hemorrhage > 500 mL was also lower in the experimental group (4, 1." | 2.78 | Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. ( Ark, C; Asıcıoğlu, O; Besımoglu, B; Gungorduk, K; Tekirdağ, Aİ; Yıldırım, G, 2013) |
| "Postpartum hemorrhage is the number one cause of severe morbidity during hospitalization for birth, despite hospital, state, and national initiatives." | 2.72 | Goals for Collaborative Management of Obstetric Hemorrhage. ( Baird, SM; Kennedy, MBB; Martin, S, 2021) |
| "Neonatal bleeding was described in 6 affected male neonates, mostly after instrumental delivery or emergency CS, but insufficient information was provided to reliably investigate neonatal outcome in relation to management." | 2.72 | Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. ( Bloemenkamp, KWM; Driessens, MHE; Duvekot, JJ; Eikenboom, J; Kruip, MJHA; Lely, AT; Makelburg, ABU; Mauser-Bunschoten, EP; Middeldorp, JM; Nieuwenhuizen, L; Peters, M; Punt, MC; Schutgens, REG; van Galen, KPM; Waning, ML, 2021) |
| " While most studies to date have focused on empirical and one-size-fit-all dosing of TXA, more selective and individualized treatment protocols (possibly guided by functional coagulation assays) are needed to pave the way for safer and more effective use of this inexpensive and widely used medication." | 2.72 | Tranexamic acid and obstetric hemorrhage: give empirically or selectively? ( Javidroozi, M; Sentilhes, L; Shander, A, 2021) |
| "The occurrences of postpartum hemorrhage (blood lose > or = 400 ml) were 6." | 2.70 | [Clinical study on the efficacy of tranexamic acid in reducing postpartum blood lose: a randomized, comparative, multicenter trial]. ( Shi, C; Yang, H; Zheng, S, 2001) |
| "TXA concentrations of 10-15 mg/l may be suitable targets for pharmacokinetic studies, although TXA concentrations above 5 mg/l may also be effective." | 2.61 | What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. ( Medcalf, RL; Picetti, R; Roberts, I; Shakur-Still, H; Standing, JF, 2019) |
| "For the treatment of postpartum hemorrhage, early use of TXA has the potential to reduce mortality." | 2.61 | Next Generation Medical Management of Postpartum Hemorrhage. ( Ahmadzia, HK; Phillips, JM; van den Anker, JN, 2019) |
| "Tranexamic acid (TXA) has been used to treat peripartum hemorrhage, while preoperative use of TXA in cesarean section (CS) remains controversial." | 2.61 | Prophylactic use of tranexamic acid reduces blood loss and transfusion requirements in patients undergoing cesarean section: A meta-analysis. ( He, L; Liu, S; Wang, Y, 2019) |
| "Tranexamic acid (TxA) has been shown to reduce death in bleeding trauma patients safely and is effective in reducing bleeding in surgical patients, however its role in PPH has been less well established." | 2.58 | Post-partum haemorrhage and tranexamic acid: a global issue. ( Hibbs, SP; Hunt, BJ; Roberts, I; Shakur-Still, H, 2018) |
| "In women with postpartum hemorrhage, the need to transfuse a large amount of blood products is frequent." | 2.58 | Postpartum Hemorrhage: Management of Massive Transfusion. ( DeLoughery, TG; Jackson, DL, 2018) |
| "Tranexamic acid (TXA) has been investigated as a potential adjunct therapy to uterotonics within this setting." | 2.58 | Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes. ( Ahmadzia, HK; James, AH; Katler, QS; Phillips, JM, 2018) |
| " The effectiveness of treatment methods and the optimal dosage of misoprostol are research priorities." | 2.53 | Preventing deaths due to haemorrhage. ( Hofmeyr, GJ; Qureshi, Z, 2016) |
| "Tranexamic acid (TA), which is an antifibrinolytic agent that is used widely to prevent and treat haemorrhage, merits evaluation to assess whether it meets these criteria." | 2.52 | Tranexamic acid for preventing postpartum haemorrhage. ( Cluver, C; Hofmeyr, GJ; Novikova, N, 2015) |
| "The morbidity and mortality of postpartum hemorrhage (PPH) in women with an underlying bleeding disorder requires vigilance by the hematologist." | 2.52 | An update on the management of bleeding disorders during pregnancy. ( Kouides, PA, 2015) |
| "Tranexamic acid (TXA) is a possible prophylactic treatment for the prevention of PPH." | 2.52 | Prophylactic Use of Tranexamic Acid for Postpartum Bleeding Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Alam, A; Choi, S, 2015) |
| "Tranexamic acid, which is an antifibrinolytic that is used widely to prevent and treat haemorrhage, merits evaluation to assess whether it meets these criteria." | 2.46 | Tranexamic acid for preventing postpartum haemorrhage. ( Hofmeyr, GJ; Novikova, N, 2010) |
| "Oxytocin loss was observed in 7 out of 22 (32%) of combinations tested." | 1.91 | The compatibility of oxytocin and tranexamic acid injection products when mixed for co-administration by infusion for the treatment of postpartum haemorrhage: An in vitro investigation. ( Ammerdorffer, A; Chinery, L; Coomarasamy, A; Gallos, ID; Gülmezoglu, AM; Lambert, P; McEvoy, C; Tomazzini, A; Wright, P, 2023) |
| "Placenta previa affects approximately 4 per 1000 pregnancies and increases the risk of antepartum bleeding, emergent preterm labour and emergency caesarean sections." | 1.91 | Use of tranexamic acid (TXA) to reduce preterm birth and other adverse obstetrical outcomes among pregnant individuals with placenta previa: a systematic review protocol. ( Muldoon, KA; Seguin, N; Visintini, S; Walker, M, 2023) |
| "Tranexamic acid (TXA) has been shown to reduce PPH complications although it is not routinely recommended for use as prophylaxis to date." | 1.91 | Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis. ( Ahmadzia, HK; Dazelle, WDH; Ebner, MK; Kazma, J; Potarazu, SN, 2023) |
| "To describe maternal deaths from postpartum hemorrhage (PPH) in Kenya by secondary analysis of the Kenya Confidential Enquiry into Maternal Deaths (CEMD) database and clinical audit of a sample of those deaths, and to identify the perceived challenges to implementing country-specific PPH guidelines." | 1.72 | A synthesis of clinical and health system bottlenecks to implementing new WHO postpartum hemorrhage recommendations: Secondary data analysis of the Kenya Confidential Enquiry into Maternal Deaths 2014-2017. ( Allott, H; Ameh, CA; Dickinson, F; Godia, P; Meka, RJ; West, F, 2022) |
| "Postpartum Hemorrhage is still the leading cause of maternal mortality." | 1.62 | [Obstetric Surgery with High Risk of Postpartum Hemorrhage in a Jehovah's Witness]. ( Carp, M; Lança, F; Maurício, S, 2021) |
| "Tranexamic acid (TXA) is an antifibrinolytic pharmacologic agent with demonstrated effectiveness for reducing the incidence of death from blood loss following trauma and major surgery." | 1.56 | The Use of Tranexamic Acid to Prevent Postpartum Hemorrhage. ( Mielke, RT; Obermeyer, S, 2020) |
| "Uterine atony is the primary cause of post-partum haemorrhage." | 1.51 | [Post-partum transfusion: The view of the anaesthetist in a delivery room]. ( Langlois, C, 2019) |
| "Tranexamic acid appears to be a safe and effective option in the treatment of obstetric hemorrhage." | 1.46 | Tranexamic Acid for the Management of Obstetric Hemorrhage. ( Chiossi, G; Costantine, MM; Hankins, GDV; Pacheco, LD; Saad, AF; Saade, GR, 2017) |
| "The delivery was complicated by postpartum hemorrhage, which resolved with the addition of uterotonic agents." | 1.43 | Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. ( Andrews, J; Dolan, S; Matei, A; Rivard, GÉ, 2016) |
| "To assess the management of postpartum hemorrhage (PPH) by anaesthesiologists in Pays de la Loire area." | 1.40 | [Declarative survey about postpartum haemorrhage management by anaesthesiologists in Pays de la Loire area (France): what's the adherence to clinical practice guidelines?]. ( Bouvet, C; Branger, B; Granry, JC; Lehousse, T; Sentilhes, L, 2014) |
| "Transfusion therapy in postpartum hemorrhage (PPH) traditionally has been modeled after precedents set in the Vietnam and Korean wars." | 1.38 | Postpartum hemorrhage management in 2012: predicting the future. ( Green, D; Keith, L; Onwuemene, O, 2012) |
| "Glanzmann's thrombasthenia is a congenitally acquired platelet disorder with an autosomal recessive mode of inheritance." | 1.33 | Pregnancy in a patient of Glanzmann's thrombasthenia. ( Chanana, C; Deka, D; Malhotra, N, 2006) |
| "Acquired haemophilia was diagnosed following detailed investigation of a post-partum haemorrhage unresponsive to standard management." | 1.31 | Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage. ( Howland, EJ; Keay, SD; Lumley, M; Palmer, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.48) | 18.2507 |
| 2000's | 7 (3.33) | 29.6817 |
| 2010's | 106 (50.48) | 24.3611 |
| 2020's | 96 (45.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bellos, I | 2 |
| Pergialiotis, V | 2 |
| Brignardello-Petersen, R | 1 |
| El Alayli, A | 1 |
| Husainat, N | 1 |
| Kalot, MA | 1 |
| Shahid, S | 1 |
| Aljabirii, Y | 1 |
| Britt, A | 1 |
| Alturkmani, H | 1 |
| El-Khechen, H | 1 |
| Motaghi, S | 1 |
| Roller, J | 1 |
| Abdul-Kadir, R | 2 |
| Couper, S | 1 |
| Kouides, P | 1 |
| Lavin, M | 1 |
| Ozelo, MC | 1 |
| Weyand, A | 1 |
| James, PD | 1 |
| Connell, NT | 1 |
| Flood, VH | 1 |
| Mustafa, RA | 1 |
| Smith, CT | 1 |
| Arnolds, DE | 2 |
| Lim, G | 1 |
| Bamber, JH | 1 |
| Ali, IAM | 1 |
| Shander, A | 2 |
| Javidroozi, M | 2 |
| Sentilhes, L | 24 |
| Deneux-Tharaux, C | 19 |
| Roberts, I | 20 |
| Ker, K | 7 |
| Ferrari, FA | 1 |
| Garzon, S | 1 |
| Raffaelli, R | 1 |
| Cromi, A | 1 |
| Casarin, J | 1 |
| Ghezzi, F | 1 |
| Uccella, S | 1 |
| Franchi, M | 1 |
| Grassin-Delyle, S | 2 |
| Semeraro, M | 1 |
| Lamy, E | 1 |
| Urien, S | 1 |
| Runge, I | 1 |
| Foissac, F | 1 |
| Bouazza, N | 1 |
| Treluyer, JM | 1 |
| Arribas, M | 3 |
| Shakur-Still, H | 16 |
| Ogunkua, OT | 1 |
| Duryea, EL | 1 |
| Nelson, DB | 1 |
| Eddins, MM | 1 |
| Klucsarits, SE | 1 |
| McIntire, DD | 1 |
| Leveno, KJ | 1 |
| Obermeyer, S | 2 |
| Mielke, RT | 2 |
| Lederhos, HL | 1 |
| Binyamin, Y | 1 |
| Orbach-Zinger, S | 1 |
| Gruzman, I | 1 |
| Frenkel, A | 1 |
| Lerman, S | 1 |
| Zlotnik, A | 1 |
| Frank, D | 1 |
| Ioscovich, A | 1 |
| Erez, O | 1 |
| Heesen, M | 4 |
| Madar, H | 9 |
| Howard, DC | 1 |
| Jones, AE | 1 |
| Skeith, A | 1 |
| Lai, J | 1 |
| D'Souza, R | 1 |
| Caughey, AB | 1 |
| Igboke, FN | 1 |
| Obi, VO | 1 |
| Dimejesi, BI | 1 |
| Lawani, LO | 1 |
| Brenner, A | 5 |
| Balogun, E | 3 |
| Bello, FA | 1 |
| Chaudhri, R | 6 |
| Fleming, C | 1 |
| Javaid, K | 2 |
| Kayani, A | 3 |
| Lubeya, MK | 1 |
| Mansukhani, R | 1 |
| Olayemi, O | 2 |
| Prowse, D | 2 |
| Vwalika, B | 2 |
| Abu-Zaid, A | 2 |
| Baradwan, S | 2 |
| Alshahrani, MS | 1 |
| Bakhsh, H | 1 |
| Badghish, E | 1 |
| Khadawardi, K | 2 |
| AlRasheed, MA | 1 |
| Turkistani, A | 1 |
| AlNaim, NF | 1 |
| AlNaim, LF | 1 |
| Fodaneel, M | 1 |
| AbuAlsaud, FS | 1 |
| Jamjoom, MZ | 1 |
| Tulbah, M | 1 |
| Almugbel, M | 1 |
| Alomar, O | 2 |
| Al-Jundi, H | 1 |
| Allam, HS | 1 |
| Alabdrabalamir, S | 1 |
| Salem, H | 2 |
| Al-Badawi, IA | 1 |
| Tran, NT | 2 |
| Schulte-Hillen, C | 2 |
| Bar-Zeev, S | 2 |
| Chidanyika, A | 1 |
| Zeck, W | 2 |
| Angarita, AM | 1 |
| Berghella, V | 5 |
| Le Lous, M | 2 |
| Sénat, MV | 4 |
| Winer, N | 4 |
| Rozenberg, P | 2 |
| Kayem, G | 3 |
| Verspyck, E | 2 |
| Fuchs, F | 3 |
| Azria, E | 3 |
| Gallot, D | 2 |
| Korb, D | 2 |
| Desbrière, R | 3 |
| Le Ray, C | 4 |
| Chauleur, C | 2 |
| de Marcillac, F | 2 |
| Perrotin, F | 5 |
| Parant, O | 2 |
| Salomon, LJ | 2 |
| Gauchotte, E | 2 |
| Bretelle, F | 2 |
| Sananès, N | 2 |
| Bohec, C | 3 |
| Mottet, N | 2 |
| Legendre, G | 4 |
| Letouzey, V | 2 |
| Haddad, B | 2 |
| Vardon, D | 4 |
| Mattuizzi, A | 3 |
| Froeliger, A | 3 |
| Bouchghoul, H | 2 |
| Daniel, V | 5 |
| Regueme, S | 2 |
| Roussillon, C | 2 |
| Georget, A | 3 |
| Darsonval, A | 4 |
| Benard, A | 4 |
| Muhunthan, K | 2 |
| Ahmadzia, HK | 10 |
| Faraoni, D | 4 |
| Ammerdorffer, A | 3 |
| Rushwan, S | 1 |
| Timms, R | 2 |
| Wright, P | 2 |
| Beeson, L | 2 |
| Devall, AJ | 5 |
| Mammoliti, KM | 2 |
| Alwy Al-Beity, FM | 1 |
| Galadanci, H | 2 |
| Hofmeyr, GJ | 9 |
| Singata-Madliki, M | 2 |
| Qureshi, Z | 3 |
| Lambert, P | 2 |
| Gallos, ID | 6 |
| Coomarasamy, A | 7 |
| Gülmezoglu, AM | 4 |
| Ameh, CA | 1 |
| Meka, RJ | 1 |
| West, F | 1 |
| Dickinson, F | 1 |
| Allott, H | 1 |
| Godia, P | 1 |
| Strauss, ER | 1 |
| VanDyck, K | 1 |
| Mazzeffi, MA | 1 |
| Jones, AJ | 1 |
| Federspiel, JJ | 1 |
| Eke, AC | 2 |
| Castle, D | 1 |
| Desborough, MJR | 2 |
| Kemp, M | 1 |
| Lowe, G | 1 |
| Thomas, W | 2 |
| Obaji, S | 2 |
| Ducloy-Bouthors, AS | 8 |
| Gilliot, S | 3 |
| Kyheng, M | 1 |
| Turbelin, A | 1 |
| Keita-Meyer, H | 2 |
| Rigouzzo, A | 1 |
| Moyanotidou, G | 1 |
| Constant, B | 1 |
| Broisin, F | 2 |
| Gouez, AL | 1 |
| Favier, R | 1 |
| Peynaud, E | 1 |
| Ghesquiere, L | 1 |
| Lebuffe, G | 3 |
| Duhamel, A | 5 |
| Allorge, D | 3 |
| Susen, S | 6 |
| Hennart, B | 5 |
| Jeanpierre, E | 6 |
| Odou, P | 3 |
| Moran, NF | 4 |
| Bishop, DG | 4 |
| Fawcus, S | 5 |
| Morris, E | 4 |
| Widmer, M | 5 |
| Oladapo, OT | 6 |
| Eyeberu, A | 3 |
| Getachew, T | 3 |
| Amare, G | 3 |
| Yadeta, E | 3 |
| Lemi, M | 3 |
| Bekele, H | 3 |
| Negash, A | 3 |
| Degefa, M | 3 |
| Balcha, T | 3 |
| Balis, B | 3 |
| Eshetu, B | 3 |
| Habte, S | 3 |
| Abdurke, M | 3 |
| Alemu, A | 3 |
| Mohammed, A | 3 |
| Ahmed, F | 3 |
| Musa, I | 3 |
| Getachew, A | 3 |
| Amin, A | 3 |
| Tefera, T | 3 |
| Debella, A | 3 |
| Karlsson, O | 2 |
| Bouthors, AS | 4 |
| Joshi, BN | 1 |
| Shetty, SS | 1 |
| Moray, KV | 1 |
| Chaurasia, H | 1 |
| Sachin, O | 1 |
| Tomazzini, A | 1 |
| McEvoy, C | 1 |
| Chinery, L | 1 |
| Litman, EA | 2 |
| Ma, P | 1 |
| Miran, SA | 1 |
| Nelson, SJ | 1 |
| Lee, SH | 1 |
| Kwek, ME | 1 |
| Tagore, S | 1 |
| Wright, A | 1 |
| Ku, CW | 1 |
| Teong, ACA | 1 |
| Tan, AWM | 1 |
| Lim, SWC | 1 |
| Yen, DYT | 1 |
| Ang, CYX | 1 |
| Sultana, R | 1 |
| Lim, CHF | 1 |
| Mathur, D | 1 |
| Mathur, M | 1 |
| Seguin, N | 1 |
| Visintini, S | 1 |
| Muldoon, KA | 1 |
| Walker, M | 1 |
| Sterling, EK | 1 |
| Dazelle, WDH | 2 |
| Alam, AQ | 1 |
| Barrett, J | 2 |
| Callum, J | 2 |
| Kaustov, L | 1 |
| Au, S | 2 |
| Fleet, A | 1 |
| Kiss, A | 2 |
| Choi, S | 3 |
| Munoz, JL | 1 |
| Blankenship, LM | 1 |
| Ramsey, PS | 1 |
| McCann, GA | 1 |
| Pacheco, LD | 3 |
| Clifton, RG | 1 |
| Saade, GR | 3 |
| Weiner, SJ | 1 |
| Parry, S | 1 |
| Thorp, JM | 1 |
| Longo, M | 1 |
| Salazar, A | 1 |
| Dalton, W | 1 |
| Tita, ATN | 1 |
| Gyamfi-Bannerman, C | 1 |
| Chauhan, SP | 1 |
| Metz, TD | 1 |
| Rood, K | 1 |
| Rouse, DJ | 2 |
| Bailit, JL | 1 |
| Grobman, WA | 1 |
| Simhan, HN | 1 |
| Macones, GA | 1 |
| Ebner, MK | 1 |
| Kazma, J | 1 |
| Potarazu, SN | 1 |
| Gallos, I | 1 |
| Devall, A | 1 |
| Martin, J | 1 |
| Middleton, L | 1 |
| Alwy Al-Beity, F | 1 |
| Moran, N | 1 |
| Sheikh, L | 1 |
| Gwako, G | 1 |
| Osoti, A | 1 |
| Aswat, A | 1 |
| Sindhu, KN | 1 |
| Podesek, M | 1 |
| Horne, I | 1 |
| Yunas, I | 1 |
| Okore, J | 1 |
| Arends, E | 1 |
| Wakili, AA | 1 |
| Mwampashi, A | 1 |
| Nausheen, S | 1 |
| Muhammad, S | 1 |
| Latthe, P | 1 |
| Evans, C | 1 |
| Akter, S | 1 |
| Forbes, G | 1 |
| Lissauer, D | 1 |
| Meher, S | 1 |
| Weeks, A | 1 |
| Shennan, A | 1 |
| Williams, E | 1 |
| Roberts, T | 1 |
| Lorencatto, F | 1 |
| Bohren, MA | 1 |
| Miller, S | 2 |
| Althabe, F | 1 |
| Gülmezoglu, M | 2 |
| Smith, JM | 1 |
| Hemming, K | 1 |
| Bouvet, L | 2 |
| Rackelboom, T | 1 |
| Morau, E | 1 |
| Yang, F | 1 |
| Wang, H | 1 |
| Shen, M | 1 |
| Cheema, HA | 1 |
| Ahmad, AB | 1 |
| Ehsan, M | 1 |
| Shahid, A | 2 |
| Ayyan, M | 1 |
| Azeem, S | 1 |
| Hussain, A | 1 |
| Nashwan, AJ | 1 |
| Mikuš, M | 1 |
| Laganà, AS | 1 |
| Boatin, AA | 1 |
| Ngonzi, J | 1 |
| Buchholz, A | 1 |
| Hansen, K | 1 |
| Rodel, R | 1 |
| Dawoud, M | 1 |
| Al-Husseiny, M | 1 |
| Helal, O | 1 |
| Elsherbini, M | 1 |
| Abdel-Rasheed, M | 1 |
| Sediek, M | 1 |
| Petit, S | 1 |
| Albouq, B | 1 |
| Ghazi, A | 1 |
| Bukhari, IA | 1 |
| Alyousef, A | 1 |
| Abdulmalik, NA | 1 |
| Alblewi, H | 1 |
| Alsehaimi, SO | 1 |
| Albadawi, MI | 1 |
| Abuzaid, M | 1 |
| Singleton, L | 1 |
| Kennedy, C | 1 |
| Philip, B | 1 |
| Navaei, A | 1 |
| Bhar, S | 1 |
| Ankola, A | 1 |
| Ontaneda, A | 1 |
| Al-Dardery, NM | 1 |
| Abdelwahab, OA | 1 |
| Abouzid, M | 1 |
| Albakri, K | 1 |
| Elkhadragy, A | 1 |
| Katamesh, BE | 1 |
| Hamamreh, R | 1 |
| Mohd, AB | 1 |
| Abdelaziz, A | 1 |
| Khaity, A | 1 |
| Muganyizi, P | 1 |
| Javid, K | 1 |
| Bello, A | 2 |
| Langlois, C | 1 |
| Fahrenholtz, CG | 1 |
| Bonanno, LS | 1 |
| Martin, JB | 1 |
| Dresang, L | 1 |
| Kredit, S | 1 |
| Vellardita, L | 1 |
| Cai, J | 1 |
| Ribkoff, J | 1 |
| Olson, S | 1 |
| Raghunathan, V | 1 |
| Al-Samkari, H | 1 |
| DeLoughery, TG | 2 |
| Shatzel, JJ | 1 |
| Xia, Y | 1 |
| Griffiths, BB | 1 |
| Xue, Q | 1 |
| Diop, A | 1 |
| Abbas, D | 1 |
| Ngoc, NTN | 1 |
| Martin, R | 1 |
| Razafi, A | 1 |
| Tuyet, HTD | 1 |
| Winikoff, B | 1 |
| Balakumar, S | 1 |
| Navaratnaraja, TS | 1 |
| Premakrishna, S | 1 |
| Arulkumaran, S | 4 |
| Tang, E | 1 |
| Stetz, J | 1 |
| Shakur, H | 7 |
| Beaumont, D | 4 |
| Pavord, S | 2 |
| Gayet-Ageron, A | 2 |
| Mousa, HA | 2 |
| Benhamou, D | 1 |
| Keita, H | 1 |
| Hynds, EB | 1 |
| Amdur, RL | 1 |
| Gimovsky, AC | 1 |
| James, AH | 5 |
| Luban, NLC | 3 |
| Kolin, DA | 1 |
| Bates, I | 2 |
| Scavone, BM | 1 |
| Picetti, R | 2 |
| Miller, L | 1 |
| Pepple, T | 2 |
| Asonganyi, E | 1 |
| El-Sheikh, M | 1 |
| Stortroen, NE | 1 |
| Tubog, TD | 2 |
| Shaffer, SK | 1 |
| Durand-Zaleski, I | 1 |
| Seco, A | 2 |
| Malki, M | 1 |
| Frenkiel, J | 1 |
| Torky, H | 1 |
| El-Desouky, ES | 1 |
| Abo-Elmagd, I | 1 |
| Mohamed, A | 1 |
| Abdalhamid, A | 1 |
| El-Shahat, A | 1 |
| Ahmed Sileem, S | 1 |
| Tawfick, MM | 1 |
| Abo-Louz, A | 1 |
| Hussein, A | 1 |
| Cortegiani, A | 1 |
| Absalom, AR | 1 |
| Hunt, BJ | 3 |
| Naeiji, Z | 1 |
| Delshadiyan, N | 1 |
| Saleh, S | 1 |
| Moridi, A | 1 |
| Rahmati, N | 1 |
| Fathi, M | 1 |
| Li, S | 2 |
| Guo, D | 2 |
| Miszta, A | 2 |
| Gobburu, JVS | 2 |
| Berger, JS | 2 |
| Wolberg, AS | 2 |
| van den Anker, J | 1 |
| Stämpfli, D | 1 |
| Weiler, S | 1 |
| Weiniger, CF | 1 |
| Burden, AM | 1 |
| Watkins, L | 1 |
| Kearney, L | 1 |
| Kynn, M | 1 |
| Hodgman, C | 1 |
| Nugent, R | 1 |
| Lechien, A | 1 |
| Van der Linden, P | 1 |
| Baird, SM | 1 |
| Martin, S | 1 |
| Kennedy, MBB | 1 |
| Dahmane, E | 1 |
| van den Anker, JN | 2 |
| Aziz, S | 1 |
| Rossiter, S | 1 |
| Homer, CSE | 1 |
| Wilson, AN | 1 |
| Comrie-Thomson, L | 1 |
| Scott, N | 1 |
| Vogel, JP | 2 |
| Punt, MC | 1 |
| Waning, ML | 1 |
| Mauser-Bunschoten, EP | 1 |
| Kruip, MJHA | 1 |
| Eikenboom, J | 2 |
| Nieuwenhuizen, L | 1 |
| Makelburg, ABU | 1 |
| Driessens, MHE | 1 |
| Duvekot, JJ | 1 |
| Peters, M | 1 |
| Middeldorp, JM | 1 |
| Bloemenkamp, KWM | 2 |
| Schutgens, REG | 1 |
| Lely, AT | 1 |
| van Galen, KPM | 1 |
| Bienstock, JL | 1 |
| Hueppchen, NA | 1 |
| Lowe, GC | 1 |
| Doree, C | 1 |
| Kashanian, M | 1 |
| Dadkhah, F | 1 |
| Tabatabaei, N | 1 |
| Sheikhansari, N | 1 |
| Hilbert, T | 1 |
| Coburn, M | 1 |
| Wang, X | 1 |
| Wang, Y | 2 |
| Hu, Y | 1 |
| Carp, M | 1 |
| Maurício, S | 1 |
| Lança, F | 1 |
| Oseni, RO | 1 |
| Zakari, M | 1 |
| Adamou, N | 1 |
| Umar, UA | 1 |
| Patil, V | 1 |
| Ratnayake, G | 1 |
| Fastovets, G | 1 |
| Brun, S | 3 |
| Merlot, B | 2 |
| Hankins, GDV | 2 |
| Saad, AF | 1 |
| Costantine, MM | 1 |
| Chiossi, G | 1 |
| Boama, V | 1 |
| Guinto, VT | 1 |
| Sosa, CG | 1 |
| Chassard, D | 1 |
| Godier, A | 2 |
| Letson, HL | 2 |
| Dobson, GP | 2 |
| Dennis, AT | 1 |
| Griffiths, JD | 1 |
| Maeda, Y | 1 |
| Yamamoto, K | 1 |
| Tanimoto, T | 1 |
| Kami, M | 1 |
| Yoshioka, S | 1 |
| Hinshaw, K | 1 |
| Burke, T | 1 |
| Belizán, JM | 1 |
| Fuchtner, C | 1 |
| Lalonde, A | 2 |
| Malhorta, J | 1 |
| Weeks, AD | 2 |
| Alam, A | 2 |
| Bopardikar, A | 1 |
| Dowswell, T | 1 |
| Gillissen, A | 1 |
| Henriquez, DDCA | 1 |
| van den Akker, T | 1 |
| Caram-Deelder, C | 1 |
| Wind, M | 1 |
| Zwart, JJ | 1 |
| van Roosmalen, J | 1 |
| van der Bom, JG | 1 |
| Shady, NW | 2 |
| Sallam, HF | 2 |
| Elsayed, AH | 1 |
| Abdelkader, AM | 1 |
| Ali, SS | 1 |
| Alanwar, A | 1 |
| Abbas, AM | 2 |
| Hibbs, SP | 1 |
| Al-Kadhimi, S | 1 |
| Patel, AD | 1 |
| Plaat, F | 1 |
| Li, B | 1 |
| Miners, A | 1 |
| Doma, K | 1 |
| Baptiste, AS | 2 |
| Saidi, I | 2 |
| Simon, E | 2 |
| Lannoy, D | 2 |
| Zargar, M | 1 |
| Nikbakht, R | 1 |
| Ahmadi, M | 1 |
| Van Der Linde, R | 1 |
| Favaloro, EJ | 1 |
| Fawole, B | 2 |
| O'Brien, KL | 1 |
| Shainker, SA | 2 |
| Lockhart, EL | 2 |
| Coss, C | 1 |
| Singh, M | 1 |
| Jones, J | 1 |
| Jackson, DL | 1 |
| Bannow, BS | 1 |
| Konkle, BA | 1 |
| Della Corte, L | 2 |
| Saccone, G | 4 |
| Locci, M | 2 |
| Carbone, L | 2 |
| Raffone, A | 2 |
| Giampaolino, P | 1 |
| Ciardulli, A | 1 |
| Zullo, F | 2 |
| Ducarme, G | 1 |
| Doret-Dion, M | 1 |
| Huissoud, C | 3 |
| Deruelle, P | 3 |
| Chrétien, JM | 1 |
| Peter, C | 1 |
| Dereu, D | 1 |
| Casini, A | 1 |
| Boulvain, M | 1 |
| Savoldelli, GL | 1 |
| Phillips, JM | 2 |
| Katler, QS | 1 |
| Kogutt, BK | 1 |
| Vaught, AJ | 1 |
| Medcalf, RL | 1 |
| Standing, JF | 1 |
| Raimann, FJ | 1 |
| Jennewein, L | 1 |
| Sonntagbauer, M | 1 |
| Raddatz, LM | 1 |
| Möllmann, CJ | 1 |
| Louwen, F | 1 |
| Zacharowski, K | 1 |
| Weber, CF | 1 |
| D'Alessandro, P | 1 |
| Ardino, B | 1 |
| Guida, M | 1 |
| Hoch, H | 1 |
| Stegbauer, J | 1 |
| Wiech, T | 1 |
| Barwing, J | 1 |
| Karbowski, B | 1 |
| Fehm, T | 1 |
| Rump, LC | 1 |
| Sudhof, LS | 1 |
| Einerson, BD | 1 |
| Liu, S | 1 |
| He, L | 1 |
| Elleboode, B | 1 |
| Abdel-Aleem, H | 1 |
| Alhusaini, TK | 1 |
| Abdel-Aleem, MA | 1 |
| Menoufy, M | 1 |
| Samama, CM | 2 |
| Ortmann, E | 1 |
| Besser, MW | 1 |
| Klein, AA | 1 |
| Bouvet, C | 1 |
| Lehousse, T | 1 |
| Branger, B | 1 |
| Granry, JC | 1 |
| Gilad, O | 1 |
| Merlob, P | 1 |
| Stahl, B | 1 |
| Klinger, G | 1 |
| Böhmer, J | 2 |
| Klöhr, S | 1 |
| Rossaint, R | 1 |
| van de Velde, M | 1 |
| Dudenhausen, JW | 1 |
| Straube, S | 2 |
| McClure, EM | 1 |
| Jones, B | 1 |
| Griffin, JB | 1 |
| Kamath-Rayne, BD | 1 |
| Downs, A | 1 |
| Goldenberg, RL | 1 |
| Collis, RE | 1 |
| Collins, PW | 1 |
| Carlier, C | 1 |
| Levy, JH | 1 |
| Lasocki, S | 1 |
| Dreyfus, M | 1 |
| Goffinet, F | 3 |
| Schwarz, GL | 1 |
| Helbo-Hansen, HS | 1 |
| Bouet, PE | 2 |
| Ruiz, V | 2 |
| Gillard, P | 2 |
| Descamps, P | 2 |
| Ekelund, K | 1 |
| Hanke, G | 1 |
| Stensballe, J | 1 |
| Wikkelsøe, A | 1 |
| Albrechtsen, CK | 1 |
| Afshari, A | 1 |
| Mirghafourvand, M | 1 |
| Mohammad-Alizadeh, S | 1 |
| Abbasalizadeh, F | 1 |
| Shirdel, M | 1 |
| Maillard, F | 1 |
| Novikova, N | 2 |
| Cluver, C | 1 |
| Kouides, PA | 1 |
| Simonazzi, G | 2 |
| Bisulli, M | 1 |
| Moro, E | 1 |
| Marshall, A | 1 |
| Sujata, N | 1 |
| Tobin, R | 1 |
| Kaur, R | 1 |
| Aneja, A | 1 |
| Khanna, M | 1 |
| Hanjoora, VM | 1 |
| Collins, P | 1 |
| Thachil, J | 1 |
| Matei, A | 1 |
| Dolan, S | 1 |
| Andrews, J | 1 |
| Rivard, GÉ | 1 |
| Kipnis, E | 1 |
| Tournoys, A | 1 |
| Prado-Dupont, A | 1 |
| Elkalioubie, A | 1 |
| Debize, G | 1 |
| Peynaud-Debayle, E | 1 |
| DeProst, D | 1 |
| Rauch, A | 1 |
| Edwards, P | 1 |
| Elbourne, D | 2 |
| Alfirevic, Z | 2 |
| Ronsmans, C | 2 |
| Le Gouez, A | 1 |
| Mercier, FJ | 1 |
| Vayssière, C | 1 |
| Frimat, M | 1 |
| Provôt, F | 1 |
| Hertig, A | 1 |
| Li, C | 1 |
| Gong, Y | 1 |
| Dong, L | 1 |
| Xie, B | 1 |
| Dai, Z | 1 |
| Glymph, DC | 1 |
| Vedenikina, M | 1 |
| Khouadja, H | 1 |
| Rouissi, W | 1 |
| Mahjoub, M | 1 |
| Sakhri, J | 1 |
| Beletaifa, D | 1 |
| Jazia, KB | 1 |
| Thomas, SM | 1 |
| Welsby, IJ | 1 |
| Hoffman, MR | 1 |
| Murtha, AP | 1 |
| Swamy, GK | 1 |
| Grotegut, CA | 1 |
| Chi, C | 1 |
| Kulkarni, A | 1 |
| Lee, CA | 1 |
| Kadir, RA | 2 |
| Annecke, T | 1 |
| Geisenberger, T | 1 |
| Kürzl, R | 1 |
| Penning, R | 1 |
| Heindl, B | 1 |
| Allen, E | 1 |
| Cook, L | 1 |
| Arab, TS | 1 |
| Al-Wazzan, AB | 1 |
| Maslow, K | 1 |
| Peitsidis, P | 1 |
| Bonnet, MP | 1 |
| Tesnière, A | 1 |
| Mignon, A | 1 |
| Jude, B | 1 |
| Mandelbrot, L | 1 |
| Tillouche, N | 1 |
| Fontaine, S | 1 |
| Le Goueff, F | 1 |
| Depret-Mosser, S | 1 |
| Vallet, B | 1 |
| Movafegh, A | 1 |
| Eslamian, L | 1 |
| Dorabadi, A | 1 |
| Somerset, D | 1 |
| Onwuemene, O | 1 |
| Green, D | 1 |
| Keith, L | 1 |
| Gungorduk, K | 1 |
| Asıcıoğlu, O | 1 |
| Yıldırım, G | 1 |
| Ark, C | 1 |
| Tekirdağ, Aİ | 1 |
| Besımoglu, B | 1 |
| Xu, J | 1 |
| Gao, W | 1 |
| Ju, Y | 1 |
| Sentürk, MB | 1 |
| Cakmak, Y | 1 |
| Yildiz, G | 1 |
| Yildiz, P | 1 |
| Neill, AC | 1 |
| Nixon, RM | 1 |
| Thornton, S | 1 |
| Yang, H | 1 |
| Zheng, S | 1 |
| Shi, C | 1 |
| Kopeć, I | 1 |
| Maślanko, K | 1 |
| Litmanowicz, M | 1 |
| Stefańska, E | 1 |
| Mikos, A | 1 |
| Warzocha, K | 1 |
| Malhotra, N | 1 |
| Chanana, C | 1 |
| Deka, D | 1 |
| Prabu, P | 1 |
| Parapia, LA | 1 |
| As, AK | 1 |
| Hagen, P | 1 |
| Webb, JB | 1 |
| Howland, EJ | 1 |
| Palmer, J | 1 |
| Lumley, M | 1 |
| Keay, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Tranexamic Acid After Oral, Intramuscular or Intravenous Administration: a Prospective, Randomised, Cross-over Trial in Healthy Volunteers.[NCT03777488] | Phase 1 | 15 participants (Actual) | Interventional | 2019-10-30 | Completed | ||
| Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery[NCT03856164] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2019-06-17 | Completed | ||
| Tranexamic Acid for the Prevention of Postpartum Bleeding in Women With Anaemia: an International, Randomised, Double-blind, Placebo Controlled Trial.[NCT03475342] | Phase 3 | 15,000 participants (Anticipated) | Interventional | 2019-08-24 | Recruiting | ||
| Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk[NCT02797119] | Phase 4 | 225 participants (Actual) | Interventional | 2016-03-15 | Terminated (stopped due to Study will be stopped due to the impossibility of reaching the objective of inclusions within a reasonable time frame and taking into account the recommendations of the international WOMAN study) | ||
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding[NCT05345613] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery :a Multicenter Randomised, Double Blind Placebo Controlled Trial (TRAAP2)[NCT03431805] | Phase 3 | 4,574 participants (Actual) | Interventional | 2018-03-03 | Completed | ||
| Double-blind, Randomized Controlled Trial to Assess the Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage[NCT02805426] | Phase 4 | 260 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Does Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Arthroscopic Surgery Reduce Postoperative Haemarthrosis and Improve Functional Prognosis?[NCT04855877] | Phase 4 | 104 participants (Anticipated) | Interventional | 2021-07-06 | Recruiting | ||
| Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial[NCT00872469] | Phase 3 | 20,060 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement[NCT00375258] | Phase 3 | 20,211 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Prevention of Postpartum Hemorrhage: Identifying Pregnant Women at Risk and Determining the Safe and Effective Use of Tranexamic Acid Using State-of-the-art Pharmacokinetic/Pharmacodynamics Modeling[NCT03287336] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-01-02 | Active, not recruiting | ||
| Management of Postpartum Haemorrhage and Effect of Geographic Region: A Secondary Analysis of the World Maternal Antifibrinolytic (WOMAN) Trial[NCT03166839] | 20,060 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)[NCT03326596] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2018-04-20 | Recruiting | ||
| Tranexamic Acid to Prevent Bleeding After Endoscopic Resection of Large Colorectal Polyps: A Pilot Project[NCT04559880] | Phase 4 | 25 participants (Actual) | Interventional | 2020-09-10 | Active, not recruiting | ||
| Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial[NCT03069859] | Phase 2 | 31 participants (Actual) | Interventional | 2018-03-06 | Active, not recruiting | ||
| The Efficacy and Safety of Intrauterine Misoprostol Versus Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Delivery in Patients With Placenta Previa: A Randomized Controlled Trial[NCT05340205] | Phase 4 | 81 participants (Actual) | Interventional | 2022-05-04 | Completed | ||
| The Efficacy and Safety of Tranexamic Acid Versus Uterotonic Agents in Reducing Blood Loss During and After Cesarean Section Among High-risk Patients: a Comparative Study[NCT06060327] | 444 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial[NCT02302456] | Phase 3 | 4,079 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321] | 60 participants (Actual) | Interventional | 2022-03-24 | Completed | |||
| Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study (TAPPAS): A Randomized, Placebo-controlled Double Blind Trial[NCT02806024] | Phase 4 | 14 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Evaluation of a Transfusion Therapy Using Whole Blood Versus Fractionated Blood Products in the Management of Coagulopathy in Patients Admitted to Hospital for Acute Traumatic Hemorrhage[NCT04431999] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-12-04 | Recruiting | ||
| Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941] | 40 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Evaluation of the Use of Tranexamic Acid in Tibial Osteotomies: a Randomised Controlled Clinical Trial.[NCT04785651] | 84 participants (Anticipated) | Interventional | 2021-02-22 | Recruiting | |||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial[NCT02739815] | Phase 4 | 200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section[NCT02780245] | Phase 4 | 100 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| Effects of Tranexamic Acid on Post Partum Hemorrhage by Uterine Atony After Cesarean Section Delivery: a Randomized, Placebo Controlled Trial.[NCT01599468] | Phase 4 | 74 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss[NCT03793153] | 99 participants (Actual) | Interventional | 2018-12-19 | Completed | |||
| [NCT01338454] | Phase 3 | 450 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section[NCT02350179] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total blood volume loss will be calculated in milliliters. (NCT03856164)
Timeframe: 24 hours postpartum.
| Intervention | milliliters (Mean) |
|---|---|
| Tranexamic Acid | 2274 |
| Placebo | 2407 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | µg/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 4.0 | 3.8 | 4.3 |
| Tranexamic Acid | 2.9 | 2.4 | 2.1 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 550.7 | 484.9 | 525.4 |
| Tranexamic Acid | 563.5 | 499.6 | 527.4 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | IU/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 61.7 | 63.3 | 22.1 |
| Tranexamic Acid | 81.8 | 67.0 | 20.7 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Before Surgery INTEM Clotting Time | After Delivery INTEM Clotting Time | P.O.D. 1 INTEM Clotting Time | Before Surgery EXTEM Clotting Time | After Delivery EXTEM Clotting Time | P.O.D. 1 EXTEM Clotting Time | |
| Placebo | 150.5 | 140.7 | 141.2 | 56.1 | 56.3 | 50.2 |
| Tranexamic Acid | 149.7 | 137.4 | 145.1 | 54.0 | 54.9 | 49.3 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | millimeter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before Surgery INTEM Maximum Clot Firmness | After Delivery INTEM Maximum Clot Firmness | P.O.D. 1 INTEM Maximum Clot Firmness | Before Surgery EXTEM Maximum Clot Firmness | After Delivery EXTEM Maximum Clot Firmness | P.O.D. 1 EXTEM Maximum Clot Firmness | Before Surgery FIBTEM Maximum Clot Firmness | After Delivery FIBTEM Maximum Clot Firmness | P.O.D. 1 FIBTEM Maximum Clot Firmness | |
| Placebo | 69.4 | 68.4 | 68.8 | 71.2 | 69.6 | 70.4 | 23.9 | 22.0 | 25.0 |
| Tranexamic Acid | 69.3 | 68.9 | 68.8 | 70.8 | 69.8 | 70.5 | 24.2 | 22.5 | 25.8 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 8.2 | 9.6 | 7.4 |
| Tranexamic Acid | 8.1 | 9.0 | 7.5 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Total number of units of blood transfused (whole blood, platelets, cryoprecipitate, and fresh frozen plasma) intra-operatively is a secondary outcome. (NCT02806024)
Timeframe: Pulled from operative note, completed by the time of discharge.
| Intervention | units (Mean) |
|---|---|
| Treatment Arm (Tranexamic Acid, or TXA) | 5.2 |
| Placebo Arm | 17.6 |
EBL is estimated by the surgeon and anesthesia team at the completion of the surgery (cesarean delivery &/or cesarean hysterectomy). (NCT02806024)
Timeframe: 1-3 hours (will be determined at the completion of the surgery).
| Intervention | cc (Mean) |
|---|---|
| Treatment Arm (Tranexamic Acid, or TXA) | 3116 |
| Placebo Arm | 9420 |
63 reviews available for tranexamic acid and Postpartum Hemorrhage
| Article | Year |
|---|---|
Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery: an updated meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Female; H | 2022 |
Tranexamic acid for the prevention and the treatment of primary postpartum haemorrhage: a systematic review.
Topics: Cesarean Section; Delivery, Obstetric; Female; Humans; Injections, Intravenous; Postpartum Hemorrhag | 2022 |
Prophylactic tranexamic acid among women undergoing vaginal delivery to reduce postpartum blood loss and related morbidities: A systematic review and meta-analysis of 17 randomized controlled trials.
Topics: Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Incidence; Postpartum Hemorrhage; Post | 2022 |
Evidence-based labor management: third stage of labor (part 5).
Topics: Female; Humans; Infant, Newborn; Lacerations; Methylergonovine; Misoprostol; Oxytocics; Oxytocin; Pl | 2022 |
Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Maternal Health Services; Postpartum Hemo | 2022 |
Alternative routes to intravenous tranexamic acid for postpartum hemorrhage: A systematic search and narrative review.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnan | 2022 |
Tranexamic acid for bleeding: Much more than a treatment for postpartum hemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Infant, Newborn; Male; Obstetrics; Postpartum Hemorrhage; P | 2023 |
Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone.
Topics: Female; Humans; Methylergonovine; Misoprostol; Oxytocics; Oxytocin; Postpartum Hemorrhage; Pregnancy | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis.
Topics: Africa; Antifibrinolytic Agents; Female; Hemoglobins; Humans; Postpartum Hemorrhage; Pregnancy; Tran | 2023 |
Protocol for postpartum haemorrhage including massive transfusion.
Topics: Blood Transfusion; Female; Hemostatics; Humans; Postpartum Hemorrhage; Tranexamic Acid; Uterine Iner | 2022 |
Protocol for postpartum haemorrhage including massive transfusion.
Topics: Blood Transfusion; Female; Hemostatics; Humans; Postpartum Hemorrhage; Tranexamic Acid; Uterine Iner | 2022 |
Protocol for postpartum haemorrhage including massive transfusion.
Topics: Blood Transfusion; Female; Hemostatics; Humans; Postpartum Hemorrhage; Tranexamic Acid; Uterine Iner | 2022 |
Protocol for postpartum haemorrhage including massive transfusion.
Topics: Blood Transfusion; Female; Hemostatics; Humans; Postpartum Hemorrhage; Tranexamic Acid; Uterine Iner | 2022 |
The role of tranexamic acid in the management of postpartum haemorrhage.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum H | 2022 |
The role of tranexamic acid in the management of postpartum haemorrhage.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum H | 2022 |
The role of tranexamic acid in the management of postpartum haemorrhage.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum H | 2022 |
The role of tranexamic acid in the management of postpartum haemorrhage.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum H | 2022 |
Effect of preoperative prophylactic intravenous tranexamic acid on perioperative blood loss control in patients undergoing cesarean delivery: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female | 2023 |
Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Humans; Postpartum Hemorrha | 2023 |
Tranexamic Acid in the Prevention and Treatment of Postpartum Hemorrhage: A Review.
Topics: Antifibrinolytic Agents; Female; Humans; Oxytocin; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2023 |
Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemostatics; Humans; Misoprostol; Postpartum | 2023 |
Efficacy and safety of tranexamic acid in prevention of postpartum hemorrhage: a systematic review and meta-analysis of 18,649 patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemoglobins; Humans; Nausea; Postpartum Hemor | 2023 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; Menorrhagia; Postpartum Hemorrh | 2020 |
Tranexamic acid for postpartum hemorrhage prevention in vaginal delivery: A meta-analysis.
Topics: Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Postpartum Hemorrhage; Randomized Cont | 2020 |
Coagulation changes and thromboembolic risk in COVID-19 obstetric patients.
Topics: Anticoagulants; Autoantibodies; Betacoronavirus; Blood Proteins; Cerebrovascular Disorders; Contrain | 2020 |
Prophylactic Tranexamic Acid in High-Risk Patients Undergoing Cesarean Delivery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomi | 2020 |
Goals for Collaborative Management of Obstetric Hemorrhage.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Goals; Humans; Hysterectomy; Maternal Mortality; | 2021 |
The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Female; Humans; Maternal Mortality; Postpartum Hemor | 2021 |
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Delivery, Obstetric; Female; Hemophilia A; Hemor | 2021 |
Postpartum Hemorrhage.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Fluid Therapy; Humans; Oxytocics; Postpartum Hem | 2021 |
Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Deamino Arginine Vasopressin; Disease Manageme | 2021 |
Tranexamic acid and obstetric hemorrhage: give empirically or selectively?
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Incidence; Postpartum Hemorrhage; Pregnan | 2021 |
Clinical 'pearls' of maternal critical care Part 2: sickle-cell disease in pregnancy.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antifibrinolytic Agents; Blood Transfusion; Critical Care | 2017 |
Post-partum haemorrhage and tranexamic acid: a global issue.
Topics: Female; Humans; Postpartum Hemorrhage; Randomized Controlled Trials as Topic; Tranexamic Acid | 2018 |
Clinical relevance of a p value: Does tranexamic acid save lives after trauma or postpartum hemorrhage?
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid; Treatmen | 2018 |
Antifibrinolytic drugs for treating primary postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cause of Death; Female; Humans; Maternal Mortality; Misoprostol; Postpartum | 2018 |
Transfusion Management of Obstetric Hemorrhage.
Topics: Adult; Blood Transfusion; Female; Hemostasis; Humans; Interdisciplinary Communication; Obstetrics; P | 2018 |
BET 1: Intravenous tranexamic acid for the treatment of post-partum haemorrhage.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Tranexa | 2018 |
Postpartum Hemorrhage: Management of Massive Transfusion.
Topics: Antifibrinolytic Agents; Blood Coagulation Tests; Blood Transfusion; Female; Humans; Hypothermia; Po | 2018 |
Inherited Bleeding Disorders in the Obstetric Patient.
Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia | 2018 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomized Controlled Tri | 2020 |
Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes.
Topics: Antifibrinolytic Agents; Delivery, Obstetric; Drug Administration Schedule; Female; Humans; Postpart | 2018 |
Medical management of postpartum hemorrhage: An update.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Coagulation Tests; Blood Transfusion; Fema | 2019 |
Postpartum hemorrhage: Blood product management and massive transfusion.
Topics: Antifibrinolytic Agents; Blood Transfusion; Clinical Protocols; Delivery, Obstetric; Female; Humans; | 2019 |
What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies.
Topics: Antifibrinolytic Agents; Female; Fibrinolysis; Humans; Male; Postpartum Hemorrhage; Pregnancy; Tissu | 2019 |
Prophylactic use of tranexamic acid after vaginal delivery reduces the risk of primary postpartum hemorrhage.
Topics: Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Oxytocin; Postpartum Hemorrhage; Pregn | 2020 |
Next Generation Medical Management of Postpartum Hemorrhage.
Topics: Antifibrinolytic Agents; Female; Fibrinogen; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Ac | 2019 |
Tranexamic acid for post-partum haemorrhage: What, who and when.
Topics: Antifibrinolytic Agents; Female; Humans; Parturition; Postpartum Hemorrhage; Postpartum Period; Preg | 2019 |
Prophylactic use of tranexamic acid reduces blood loss and transfusion requirements in patients undergoing cesarean section: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Female; Humans; | 2019 |
Tranexamic acid for childbirth: why, when, and for whom.
Topics: Antifibrinolytic Agents; Female; Humans; Parturition; Postpartum Hemorrhage; Pregnancy; Tranexamic A | 2019 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Prophylactic tranexamic acid in parturients at low risk for post-partum haemorrhage: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranex | 2014 |
Tranexamic acid to reduce postpartum hemorrhage: A MANDATE systematic review and analyses of impact on maternal mortality.
Topics: Africa South of the Sahara; Antifibrinolytic Agents; Birth Rate; Community Health Centers; Developin | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
Haemostatic management of obstetric haemorrhage.
Topics: Blood Transfusion; Factor VIIa; Female; Fibrinogen; Hemostasis; Hemostatic Techniques; Humans; Plasm | 2015 |
[Efficacy and safety of tranexamic acid administration for the prevention and/or the treatment of post-partum haemorrhage: a systematic review with meta-analysis].
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2014 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Fetus; Humans; Postpartum Hemorrhage; Pregnancy; | 2015 |
Hemostatic resuscitation in postpartum hemorrhage - a supplement to surgery.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Coagulation Tests; Blood Transfusion; Crys | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2015 |
An update on the management of bleeding disorders during pregnancy.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Female; Hemorrhagic | 2015 |
Prophylactic Use of Tranexamic Acid for Postpartum Bleeding Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Antifibrinolytic Agents; Chemoprevention; Female; Humans; Postpartum Hemorrhage; Pregnancy; R | 2015 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemoglobins; Humans; Oxytocics; Postoperative He | 2016 |
Preventing deaths due to haemorrhage.
Topics: Abruptio Placentae; Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Crystalloid Soluti | 2016 |
Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials.
Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Parturition; Postpartum Hemorrh | 2016 |
Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials.
Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Parturition; Postpartum Hemorrh | 2016 |
Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials.
Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Parturition; Postpartum Hemorrh | 2016 |
Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials.
Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Parturition; Postpartum Hemorrh | 2016 |
Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention?: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Cesarean Section; Chemoprevention; Female; Humans; Natural Childbirth; Post | 2017 |
AANA Journal Course: Update for Nurse Anesthetists-Part 5-Use of Tranexamic Acid in Preventing Postpartum Hemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Nurse Anesthetists; Postpartum Hemorrhage; Pregnancy; Trane | 2016 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Tranexamic acid for preventing postpartum haemorrhage.
Topics: Aminobenzoates; Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrh | 2010 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
[Transfusion for post-partum haemorrhage: what's new in 2011?].
Topics: Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Clinical Trials as Topic; Combined Mod | 2011 |
50 trials available for tranexamic acid and Postpartum Hemorrhage
| Article | Year |
|---|---|
Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antifibrinolytic Agents; Cross-Over Studie | 2022 |
Tranexamic acid for prevention of hemorrhage in elective repeat cesarean delivery-a randomized study.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Placenta; Postpartum Hemorrhage; Pregnanc | 2022 |
Tranexamic acid for reducing blood loss following vaginal delivery: a double-blind randomized controlled trial.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Volume; Delivery, Obstetric; Doub | 2022 |
Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery randomized clinical trial.
Topics: Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Female; Humans; Postpartum Hemorrhage; | 2022 |
Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; Cesarean Section; Double-Blind Met | 2022 |
Tranexamic acid, as an adjunct to oxytocin prophylaxis, in the prevention of postpartum haemorrhage in women undergoing elective caesarean section: A single-centre double-blind randomised controlled trial.
Topics: Cesarean Section; Double-Blind Method; Female; Hemoglobins; Humans; Infant, Newborn; Oxytocin; Postp | 2023 |
Tranexamic acid for the prevention of postpartum haemorrhage: the TAPPH-1 pilot randomized trial and lessons learned for trials in Canadian obstetrics.
Topics: Antifibrinolytic Agents; Canada; Female; Humans; Pilot Projects; Postpartum Hemorrhage; Pregnancy; T | 2023 |
Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Chemoprevention; | 2023 |
Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage.
Topics: Early Diagnosis; Female; Humans; Oxytocics; Postpartum Hemorrhage; Pregnancy; Risk; Tranexamic Acid | 2023 |
Intravenous tranexamic acid vs. sublingual misoprostol in high-risk women for postpartum haemorrhage following cesarean delivery; a randomised clinical trial.
Topics: Blood Loss, Surgical; Cesarean Section; Female; Humans; Misoprostol; Oxytocin; Postoperative Hemorrh | 2023 |
Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I'M WOMAN).
Topics: Administration, Intravenous; Antifibrinolytic Agents; Cesarean Section; Delivery, Obstetric; Female; | 2023 |
TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Cesarean Section; Double-Blind Method; Female; | 2020 |
A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; | 2020 |
Plasma Concentrations of Tranexamic Acid in Postpartum Women After Oral Administration.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Chromatography, High Pressure Liquid; Female; | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
The WOMAN trial: clinical and contextual factors surrounding the deaths of 483 women following post-partum haemorrhage in developing countries.
Topics: Adult; Africa; Anemia; Antifibrinolytic Agents; Asia; Blood Transfusion; Cause of Death; Cesarean Se | 2020 |
An economic evaluation of tranexamic acid to prevent postpartum haemorrhage in women with vaginal delivery: the randomised controlled TRAAP trial.
Topics: Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Delivery, Obstetric; Female; France; Hospital | 2021 |
Pre-operative tranexemic acid vs. etamsylate in reducing blood loss during elective cesarean section: randomized controlled trial.
Topics: Adult; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Double-Blind Method; Elective Surg | 2021 |
Prophylactic use of tranexamic acid for decreasing the blood loss in elective cesarean section: A placebo-controlled randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cesarean Section; Double-Bl | 2021 |
Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator-induced hyperfibrinolysis in full-term pregnant women: a prospective interventional study.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Fibrinolysis; Humans; Post | 2021 |
Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Do | 2021 |
Effects of tranexamic acid on the amount of bleeding following vaginal delivery and its adverse effects: a double-blind placebo controlled randomized clinical trial.
Topics: Antifibrinolytic Agents; Delivery, Obstetric; Double-Blind Method; Female; Hemoglobins; Humans; Post | 2022 |
Effectiveness of preoperative tranexamic acid in reducing blood loss during caesarean section at Aminu Kano Teaching Hospital, Kano: a randomized controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2021 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Administration Schedule; Femal | 2017 |
Protocol for a pilot, randomised, double-blinded, placebo-controlled trial of prophylactic use of tranexamic acid for preventing postpartum haemorrhage (TAPPH-1).
Topics: Antifibrinolytic Agents; Double-Blind Method; Feasibility Studies; Female; Humans; Off-Label Use; Pi | 2017 |
The effect of prophylactic oral tranexamic acid plus buccal misoprostol on blood loss after vaginal delivery: a randomized controlled trial.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Misoprostol; Oxytocics; Postpartum Hemorrhage; Pregn | 2019 |
Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Female; Humans; Nigeria; Pakistan; Postpartum Hemorr | 2018 |
Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Dr | 2018 |
The Effect of Tranexamic Acid on Preventing Post-partum Hemorrhage Due to Uterine Atony: A Triple-blind Randomized Clinical Trial.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Humans; Injections, Intravenous; Postop | 2018 |
The impact of early outcome events on the effect of tranexamic acid in post-partum haemorrhage: an exploratory subgroup analysis of the WOMAN trial.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Hysterectomy; Maternal Death; Odds Ratio; Postpartum | 2018 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2019 |
Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial.
Topics: Africa; Anemia; Antifibrinolytic Agents; Asia; Biomarkers; Double-Blind Method; Female; Hemoglobins; | 2018 |
Effectiveness of tranexamic acid on blood loss in patients undergoing elective cesarean section: randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Elective Surgical Procedures | 2013 |
Outcome following tranexamic acid exposure during breastfeeding.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Child, Preschool; Drug Administration Schedule; Fail | 2014 |
Outcome following tranexamic acid exposure during breastfeeding.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Child, Preschool; Drug Administration Schedule; Fail | 2014 |
Outcome following tranexamic acid exposure during breastfeeding.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Child, Preschool; Drug Administration Schedule; Fail | 2014 |
Outcome following tranexamic acid exposure during breastfeeding.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Child, Preschool; Drug Administration Schedule; Fail | 2014 |
The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum haemorrhage: a double-blind randomised controlled trial.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Volume; Double-Blind Method; Fema | 2015 |
Study protocol. TRAAP - TRAnexamic Acid for Preventing postpartum hemorrhage after vaginal delivery: a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Delivery, Obstetric; Double | 2015 |
Study protocol. TRAAP - TRAnexamic Acid for Preventing postpartum hemorrhage after vaginal delivery: a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Delivery, Obstetric; Double | 2015 |
Study protocol. TRAAP - TRAnexamic Acid for Preventing postpartum hemorrhage after vaginal delivery: a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Delivery, Obstetric; Double | 2015 |
Study protocol. TRAAP - TRAnexamic Acid for Preventing postpartum hemorrhage after vaginal delivery: a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Delivery, Obstetric; Double | 2015 |
Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery.
Topics: Adult; Antifibrinolytic Agents; Female; Ferric Compounds; Ferric Oxide, Saccharated; France; Glucari | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; | 2016 |
Postpartum haemorrhage related early increase in D-dimers is inhibited by tranexamic acid: haemostasis parameters of a randomized controlled open labelled trial.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Specimen Collection; Female; Fibrin Fibrin | 2016 |
The effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Clinical Protocols; Data Interpretation, Statistical; Fe | 2016 |
The effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Clinical Protocols; Data Interpretation, Statistical; Fe | 2016 |
The effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Clinical Protocols; Data Interpretation, Statistical; Fe | 2016 |
The effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Clinical Protocols; Data Interpretation, Statistical; Fe | 2016 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Topics: Adult; Antifibrinolytic Agents; Breast Feeding; Double-Blind Method; Female; Hemodynamics; Humans; H | 2010 |
Post-partum haemorrhage and the WOMAN trial.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2010 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage.
Topics: Adult; Antifibrinolytic Agents; Dose-Response Relationship, Drug; Female; Humans; Injections, Intrav | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2011 |
Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Delivery, Obstetric; Double-Blind Metho | 2013 |
Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section: a double-blind randomization trial.
Topics: Adult; Antifibrinolytic Agents; Cesarean Section; Double-Blind Method; Female; Humans; Postoperative | 2013 |
Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Double-Blind Method; Female; | 2013 |
[Clinical study on the efficacy of tranexamic acid in reducing postpartum blood lose: a randomized, comparative, multicenter trial].
Topics: Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Oxytocin; Postpartum Hemorrhage; Pregn | 2001 |
97 other studies available for tranexamic acid and Postpartum Hemorrhage
| Article | Year |
|---|---|
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
Topics: Female; Humans; Menorrhagia; Postpartum Hemorrhage; Pregnancy; Systematic Reviews as Topic; Tranexam | 2022 |
Tranexamic acid for obstetric hemorrhage: Prophylaxis, treatment, both, neither?
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Ac | 2021 |
Prophylactic tranexamic acid at delivery: if not now, when?
Topics: Antifibrinolytic Agents; Humans; Postpartum Hemorrhage; Tranexamic Acid | 2022 |
Reply to: Prophylactic tranexamic acid at delivery: if not now, when?
Topics: Antifibrinolytic Agents; Humans; Postpartum Hemorrhage; Tranexamic Acid | 2022 |
Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa | 2022 |
Reply: Prophylactic tranexamic acid in cesarean delivery: synthesis of evidence.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa | 2022 |
The Role of Perinatal Nurses in the Use of Tranexamic Acid During Postpartum Hemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Nurse's Role; Postpartum Hemorrhage; Pregnancy; Tranexamic | 2022 |
The effect of prophylactic use of tranexamic acid for cesarean section.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Hemoglobins; Humans; Infant | 2022 |
[What's new in obstetrics and gynecology ? About tranexamic acid for the prevention of postpartum hemorrhage].
Topics: Antifibrinolytic Agents; Female; Gynecology; Humans; Obstetrics; Postpartum Hemorrhage; Pregnancy; T | 2022 |
Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Female; Humans; Male; Maternal Death; Postpartum Hem | 2022 |
Postpartum haemorrhage in anaemic women: assessing outcome measures for clinical trials.
Topics: Anemia; Delivery, Obstetric; Female; Humans; Outcome Assessment, Health Care; Postpartum Hemorrhage; | 2022 |
How to use heat-stable carbetocin and tranexamic acid for the prevention and treatment of postpartum haemorrhage in low-resource settings.
Topics: Female; Hot Temperature; Humans; Oxytocin; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2022 |
Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania.
Topics: Female; Humans; Kenya; Nigeria; Oxytocin; Postpartum Hemorrhage; Pregnancy; South Africa; Tanzania; | 2022 |
A synthesis of clinical and health system bottlenecks to implementing new WHO postpartum hemorrhage recommendations: Secondary data analysis of the Kenya Confidential Enquiry into Maternal Deaths 2014-2017.
Topics: Data Analysis; Female; Humans; Kenya; Maternal Death; Misoprostol; Oxytocics; Postpartum Hemorrhage; | 2022 |
Tranexamic acid for cesarean delivery: induction of a regimen for postpartum hemorrhage?
Topics: Antifibrinolytic Agents; Cesarean Section; Clinical Protocols; Female; Humans; Postpartum Hemorrhage | 2023 |
Outcomes and management of pregnancy in women with bleeding disorder of unknown cause.
Topics: Deamino Arginine Vasopressin; Female; Hemophilia A; Hemostatics; Humans; Postpartum Hemorrhage; Preg | 2022 |
Tranexamic acid at cesarean delivery: drug-error deaths.
Topics: Anesthetics, Local; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage | 2023 |
Tranexamic acid at cesarean delivery: drug-error deaths.
Topics: Anesthesia, Spinal; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage | 2022 |
Tranexamic acid at cesarean delivery: Drug-error deaths.
Topics: Anesthesia, Spinal; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage | 2023 |
Tranexamic acid at cesarean delivery: drug-error deaths.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Medication Errors; Postpartum Hemorrhage; | 2023 |
Cost-effectiveness and budget impact of adding tranexamic acid for management of post-partum hemorrhage in the Indian public health system.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Female; Humans; Postpartum Hemorrhage; Postpartum Pe | 2023 |
The compatibility of oxytocin and tranexamic acid injection products when mixed for co-administration by infusion for the treatment of postpartum haemorrhage: An in vitro investigation.
Topics: Antifibrinolytic Agents; Female; Humans; Infusions, Intravenous; Oxytocin; Postpartum Hemorrhage; Tr | 2023 |
Association Between Surgeon Gender and Maternal Morbidity After Cesarean Delivery.
Topics: Female; Humans; Oxytocics; Oxytocin; Postpartum Hemorrhage; Pregnancy; Prospective Studies; Surgeons | 2023 |
Recent trends in tranexamic acid use during postpartum hemorrhage in the United States.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Maternal Mortality; Postpartum Hemorrhage | 2023 |
Use of tranexamic acid (TXA) to reduce preterm birth and other adverse obstetrical outcomes among pregnant individuals with placenta previa: a systematic review protocol.
Topics: Female; Humans; Infant, Newborn; Obstetric Labor Complications; Placenta; Placenta Previa; Postpartu | 2023 |
An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021.
Topics: Antifibrinolytic Agents; Female; Humans; Peripartum Period; Postpartum Hemorrhage; Pregnancy; Retros | 2023 |
Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum.
Topics: Blood Transfusion; Cesarean Section; Hysterectomy; Placenta Accreta; Postpartum Hemorrhage; Pregnanc | 2023 |
Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Female; Humans; Postpar | 2023 |
Does tranexamic acid have its place in the prevention of postpartum hemorrhage?
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2023 |
Early Detection and Bundled Treatment for Postpartum Hemorrhage.
Topics: Antifibrinolytic Agents; Combined Modality Therapy; Early Diagnosis; Female; Humans; Postpartum Hemo | 2023 |
Tranexamic acid for reduction of blood loss after Caesarean delivery: a cost-effectiveness analysis of the TRAAP2 trial.
Topics: Antifibrinolytic Agents; Cesarean Section; Cost-Effectiveness Analysis; Female; Humans; Postpartum H | 2023 |
Inhaled tranexamic acid use for pulmonary hemorrhage in children on ECMO.
Topics: Antifibrinolytic Agents; Child; Extracorporeal Membrane Oxygenation; Female; Hemorrhage; Humans; Lun | 2023 |
[Post-partum transfusion: The view of the anaesthetist in a delivery room].
Topics: Anesthetists; Attitude of Health Personnel; Blood Transfusion; Delivery Rooms; Female; Fibrinogen; H | 2019 |
Tranexamic acid as adjuvant treatment for postpartum hemorrhage: a systematic review protocol.
Topics: Adjuvants, Pharmaceutic; Administration, Intravenous; Antifibrinolytic Agents; Female; Humans; Postp | 2019 |
Does tranexamic acid reduce mortality in women with postpartum hemorrhage?
Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy; | 2019 |
Tranexamic Acid for Postpartum Hemorrhage.
Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2020 |
Antifibrinolytic drugs for treating primary postpartum hemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2020 |
The Use of Tranexamic Acid to Prevent Postpartum Hemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Risk Factors; Tranexamic | 2020 |
National trends in tranexamic acid use in the peripartum period, 2015-2019.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Peripartum Period; Postpartum Hemorrhage; Pregnancy; | 2020 |
Tranexamic acid use for postpartum hemorrhage: A survey of Illinois birthing hospitals.
Topics: Antifibrinolytic Agents; Female; Hospitals; Humans; Illinois; Postpartum Hemorrhage; Pregnancy; Tran | 2020 |
Intramuscular tranexamic acid: a real-world application of pharmacokinetics.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2021 |
Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.
Topics: Adult; Cesarean Section; Dose-Response Relationship, Drug; Female; Fibrin Fibrinogen Degradation Pro | 2021 |
Renal ischemic adverse drug events related to tranexamic acid in women of child-bearing age: an analysis of pharmacovigilance data.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Databases, Factual; Embolism; Female; Humans; Ischemia; | 2021 |
Implementation of a guideline of early administration of tranexamic acid for severe primary postpartum haemorrhage: a retrospective comparative study.
Topics: Female; Hemoglobins; Humans; Hysterectomy; Postpartum Hemorrhage; Pregnancy; Retrospective Studies; | 2021 |
Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa | 2021 |
[Tranexamic acid for prophylaxis of postpartum hemorrhage following cesarean delivery. Comments on the TRAAP2 study].
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa | 2021 |
Effect of tranexamic acid on clinical therapeutic effect and blood coagulation function of high-risk pregnant women with postpartum hemorrhage after cesarean section.
Topics: Blood Coagulation; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Ac | 2022 |
[Obstetric Surgery with High Risk of Postpartum Hemorrhage in a Jehovah's Witness].
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Jehovah's Witnesses; Obstetric Surgical | 2021 |
Re: Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials: A very welcome publication.
Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Publishing; Tranexamic Acid | 2017 |
Tranexamic Acid for the Management of Obstetric Hemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid; Treatmen | 2017 |
Contemporary Issues in Women's Health.
Topics: Antifibrinolytic Agents; Breast Feeding; Female; Health Care Rationing; Humans; Pertussis Vaccine; P | 2017 |
Administration of tranexamic acid to reduce maternal mortality related to postpartum haemorrhage: comments on the WOMAN trial.
Topics: Antifibrinolytic Agents; Female; Humans; Maternal Mortality; Postpartum Hemorrhage; Pregnancy; Trane | 2018 |
Should we add tranexamic acid to postpartum haemorrhage protocols after the WOMAN trial publication?
Topics: Adult; Antifibrinolytic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; P | 2018 |
Tranexamic acid for post-partum haemorrhage in the WOMAN trial.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex | 2017 |
Tranexamic acid for post-partum haemorrhage in the WOMAN trial.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex | 2017 |
Tranexamic acid for post-partum haemorrhage in the WOMAN trial.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex | 2017 |
Tranexamic acid for post-partum haemorrhage in the WOMAN trial.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex | 2017 |
Tranexamic acid for post-partum haemorrhage in the WOMAN trial.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex | 2017 |
Tranexamic acid for post-partum haemorrhage in the WOMAN trial - Authors' reply.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex | 2017 |
Moving Beyond Uterotonics for the Treatment of Postpartum Hemorrhage: Lessons From the WOMAN Study.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemostatic Techniques; Humans; Hysterectomy; Mis | 2017 |
Updated WHO recommendation on intravenous tranexamic acid for the treatment of post-partum haemorrhage.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnan | 2018 |
The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study.
Topics: Adult; Female; Humans; Postpartum Hemorrhage; Pregnancy; Pregnancy Outcome; Retrospective Studies; T | 2017 |
Intrathecal tranexamic acid - an accident waiting to happen?
Topics: Adult; Anesthetics, Local; Antifibrinolytic Agents; Bupivacaine; Drug Packaging; Female; Humans; Inj | 2018 |
Tranexamic acid for postpartum haemorrhage: a major advance.
Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2018 |
Tranexamic acid to prevent post-partum haemorrhage.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex | 2018 |
[Tranexamic acid for the management of postpartum haemorrhage : current knowledge].
Topics: Antifibrinolytic Agents; Female; Humans; Maternal Mortality; Postpartum Hemorrhage; Pregnancy; Trane | 2018 |
Influence of the WOMAN trial on national wide standard operating procedures for treatment of postpartum hemorrhage.
Topics: Algorithms; Antifibrinolytic Agents; Berlin; Birth Rate; Clinical Trials as Topic; Female; Humans; O | 2019 |
[Renal cortical necrosis after application of tranexamic acid in peripartal hemorrhage].
Topics: Adult; Female; Humans; Kidney Cortex Necrosis; Postpartum Hemorrhage; Pregnancy; Renal Dialysis; Tra | 2019 |
Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis.
Topics: Adult; Antifibrinolytic Agents; Cost Savings; Cost-Benefit Analysis; Decision Trees; Female; Health | 2019 |
[Management of massive bleeding in 2013: seven questions and answers].
Topics: Acute Disease; Blood Component Transfusion; Combined Modality Therapy; Disease Management; Erythrocy | 2013 |
[Declarative survey about postpartum haemorrhage management by anaesthesiologists in Pays de la Loire area (France): what's the adherence to clinical practice guidelines?].
Topics: Adult; Anesthesiology; Blood Transfusion; Female; France; Guideline Adherence; Guidelines as Topic; | 2014 |
Prophylactic tranexamic acid in low-risk parturients.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2015 |
High-dose tranexamic acid for treating postpartum haemorrhage after vaginal delivery.
Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Postpartum Hemorrhage; Pregnanc | 2015 |
In response to the letter by Schwarz GL et al. concerning the paper by Heesen M et al.
Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid | 2015 |
Tranexamic acid for preventing postpartum blood loss at cesarean delivery: is evidence sufficient?
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomi | 2016 |
Evidence on the use of tranexamic acid at cesarean delivery.
Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomi | 2016 |
Tranexamic Acid for Prevention PPH: a Promising Drug But Today Only a Promising Drug.
Topics: Antifibrinolytic Agents; Chemoprevention; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomiz | 2016 |
Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; Blood Transfusion; Cardiology; Facto | 2016 |
Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report.
Topics: Adult; Factor VII Deficiency; Factor VIIa; Female; Hemostatics; Humans; Postpartum Hemorrhage; Pregn | 2016 |
Major obstetric hemorrhage.
Topics: Blood Component Transfusion; Combined Modality Therapy; Dinoprostone; Factor VIIa; Female; Fibrinoge | 2016 |
Comparison of postpartum haemorrhage guidelines: discrepancies underline our lack of knowledge.
Topics: Antifibrinolytic Agents; Female; Hemostatic Techniques; Humans; Oxytocics; Oxytocin; Postpartum Hemo | 2017 |
Risk of Tranexamic Acid for Treatment of Postpartum Hemorrhage.
Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Risk; Tranexamic Acid | 2017 |
In Reply to 'Risk of Tranexamic Acid for Treatment of Postpartum Hemorrhage'.
Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Risk; Tranexamic Acid | 2017 |
[Transfusion strategy for patients with severe postpartum hemorrhage: a retrospective study of 47 cases].
Topics: Adolescent; Adult; Blood Transfusion; Cesarean Section; Erythrocyte Transfusion; Factor VIIa; Female | 2016 |
Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Case-Control Studies; Female; | 2017 |
The obstetric experience of women with factor XI deficiency.
Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Factor XI; Factor XI Deficiency; Female; Humans | 2009 |
Algorithm-based coagulation management of catastrophic amniotic fluid embolism.
Topics: Acidosis; Adult; Algorithms; Blood Coagulation Factors; Blood Component Transfusion; Cardiovascular | 2010 |
Postpartum hemorrhage in a Jehovah's Witness patient controlled with Tisseel, tranexamic acid, and recombinant factor VIIa.
Topics: Adult; Antifibrinolytic Agents; Factor VIIa; Female; Fibrin Tissue Adhesive; Hemostatics; Humans; Hy | 2010 |
Pregnancy-associated breast cancer: a review for the obstetrical care provider.
Topics: Factor VIIa; Female; Fibrin Tissue Adhesive; Hemostatics; Humans; Jehovah's Witnesses; Postpartum He | 2011 |
Tranexamic acid for postpartum bleeding.
Topics: Anemia; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; | 2011 |
Postpartum hemorrhage management in 2012: predicting the future.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Fibrinogen; Humans; Point-of-Care Systems; Postp | 2012 |
A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage.
Topics: Anti-Bacterial Agents; Cesarean Section; Cohort Studies; Delivery, Obstetric; Female; Humans; Noreth | 2002 |
[Bernard-Soulier syndrome during pregnancy: a case report].
Topics: Adult; Antigens, Human Platelet; Bernard-Soulier Syndrome; Deamino Arginine Vasopressin; Female; Hum | 2005 |
Pregnancy in a patient of Glanzmann's thrombasthenia.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Patient Readmission; Platelet Transfusion; Postpartu | 2006 |
Bernard-Soulier syndrome in pregnancy.
Topics: Adolescent; Adult; Bernard-Soulier Syndrome; Blood Platelets; Consanguinity; Deamino Arginine Vasopr | 2006 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage.
Topics: Adult; Autoantibodies; Deamino Arginine Vasopressin; Factor VIII; Female; Hemophilia A; Hemostatics; | 2002 |